var docs;if (!docs) docs =[]; docs["102"]={"10200":"<p><b>Title</b> Sildenafil / Nefazodone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Specific recommendations regarding management of this interaction vary according to whether sildenafil is being used to treat pulmonary arterial hypertension or erectile dysfunction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nefazodone may increase the serum concentration of Sildenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> <u>When sildenafil is used for treatment of pulmonary arterial hypertension</u>, concurrent use with strong CYP3A4 inhibitors, such as nefazodone, is not recommended. Although the Canadian labeling for the Revatio brand of sildenafil does describe concurrent use of nefazodone as not recommended, it does describe a recommended sildenafil dose reduction to 20 mg once daily (10 mg once daily if by injection) if such a combination is used. <u>When sildenafil is used for treatment of erectile dysfunction</u>, consider using a lower starting dose of 25 mg in patients also taking a strong CYP3A4 inhibitor. The interaction between CYP3A4 inhibitors and sildenafil is predicted to be greater with orally administered than with injected sildenafil.</p> \n<p><b>Discussion</b> The average sildenafil AUC and maximum serum concentration (Cmax) were approximately 11- and 4-fold higher, respectively, when a single sildenafil dose (100 mg) was administered to individuals treated with the strong CYP3A4 inhibitor ritonavir (500 mg twice/day).<sup>1</sup> The average sildenafil AUC and Cmax were 3.1- and 2.4-fold higher, respectively, when sildenafil (100 mg x1) was administered to healthy volunteers receiving saquinavir (1200 mg three times/day),<sup>1</sup> a strong inhibitor of CYP3A4, although not as potent as ritonavir. Concurrent administration of sildenafil with the strong CYP3A4 inhibitor clarithromycin was associated with an average 2.3-fold increase in sildenafil AUC and an average 2.4-fold increase in sildenafil Cmax.<sup>2</sup> Studies with the more moderate CYP3A4 inhibitors cimetidine (800 mg) and erythromycin (500 mg twice/day) reported increases of 56% to 182% in sildenafil concentrations.<sup>3,4,5</sup><br><br>Based on these data, the sildenafil prescribing information recommends avoiding concurrent use of sildenafil with strong CYP3A4 inhibitors when sildenafil is used to treat pulmonary arterial hypertension.<sup>5,6</sup> Although the Canadian labeling for the Revatio brand of sildenafil does describe concurrent use of nefazodone as not recommended, it does describe a recommended sildenafil dose reduction to 20 mg once daily (10 mg once daily if by injection) if such a combination is used.<sup>6</sup> A lower initial sildenafil dose (25 mg) is recommended when used to treat erectile dysfunction.<sup>4</sup><br><br>The mechanism of this interaction appears to be inhibition of the CYP3A4 metabolism of sildenafil, leading to increased sildenafil concentrations/exposure and possibly to greater effects and/or toxicity. The particularly potent interaction with ritonavir may simply reflect the strong CYP3A4 inhibition of ritonavir or may be the result of additional ritonavir-mediated inhibition of CYP2C9, which is also capable of metabolizing sildenafil, although generally to a lesser extent than CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. <i>Br J Clin Pharmacol</i>. 2000;50(2):99-107. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10930961\">[PubMed 10930961]</a></p>\n<p>2. Hedaya MA, El-Afify DR, El-Maghraby GM. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. <i>Biopharm Drug Dispos</i>. 2006;27(2):103-110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16372380\">[PubMed 16372380]</a></p>\n<p>3. Muirhead GJ, Faulkner S, Harness JA, Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2002;53(suppl 1):37S-43S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11879258\">[PubMed 11879258]</a></p>\n<p>4. Viagra (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; January 2011.</p>\n<p>5. Revatio (sildenafil) [prescribing information]. New York, NY: Pfizer Inc; January 2014.</p>\n<p>6. Revatio (sildenafil) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc.; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10201":"<p><b>Title</b> Valproic Acid and Derivatives / Cholestyramine Resin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cholestyramine Resin may decrease the serum concentration of Valproic Acid and Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate administration of valproic acid and cholestyramine by at least 3 hours whenever possible in order to minimize the potential for a significant interaction. The extent to which delayed-release or extended-release valproic acid or divalproex products would be impacted by concurrent cholestyramine is uncertain.</p> \n<p><b>Discussion</b> The valproic acid AUC was an average of 15% lower when administered with cholestyramine in a three-way open-label crossover study of six healthy subjects who were given single oral doses of valproic acid 250 mg with cholestyramine 4 gm twice daily (for 24 hours preceding and following the valproic acid).<sup>1</sup> When cholestyramine was administered 3 hours after valproic acid, no significant change in valproic acid AUC was noted. It was proposed that cholestyramine caused insoluble complexes with valproic acid in the gut, leading to impaired absorption of valproic acid. The reported valproic acid bioavailability with concurrent cholestyramine was 86%, while the bioavailability with a 3 hour separation was 95%.<sup>1</sup> Administration of cholestyramine at least 3 hours after valproic acid should minimize any potential decrease in valproic acid bioavailability or activity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Malloy MJ, Ravis WR, Pennell AT, Diskin CJ. Effect of cholestyramine resin on single dose valproate pharmacokinetics. <i>Int J Clin Pharmacol Ther</i>. 1996;34(5):208-211. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8738857\">[PubMed 8738857]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10202":"<p><b>Title</b> Astemizole / Aprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Aprepitant may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of aprepitant with astemizole is contraindicated.</p> \n<p><b>Discussion</b> Given the ability of aprepitant to inhibit the CYP3A4 enzyme responsible for the metabolism of astemizole and the potential for serious toxicity with increased astemizole concentrations, the aprepitant manufacture contraindicates concurrent use of aprepitant and astemizole.<sup>1</sup> Aprepitant is a dose-dependent, moderate inhibitor of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emend (aprepitant) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc.; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10203":"<p><b>Title</b> Terfenadine / Aprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Aprepitant may increase the serum concentration of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of aprepitant with terfenadine is contraindicated.</p> \n<p><b>Discussion</b> Given the ability of aprepitant to inhibit the CYP3A4 enzyme responsible for the metabolism of terfenadine and the potential for serious toxicity with increased terfenadine concentrations, the aprepitant manufacture contraindicates concurrent use of aprepitant and terfenadine.<sup>1</sup> Aprepitant is a dose-dependent, moderate inhibitor of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emend (aprepitant) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc.; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10211":"<p><b>Title</b> CNS Depressants / Trimeprazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimeprazine may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased CNS depressant effects (eg, somnolence, dizziness, reduced mental alertness) if trimeprazine is combined with a CNS depressant. Initiation of trimeprazine in patients already in a state of CNS depression caused by a CNS depressant is contraindicated.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Product labeling for trimeprazine states that CNS depressants and trimeprazine should be coadministered with caution, as the CNS depressant effects of each agent may be additive.<sup>1</sup> The use of trimeprazine in patients already in a state of CNS depression caused by CNS depressant drugs is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Panectyl (trimeprazine) [product monograph]. Montreal, Quebec, Canada: ERFA Canada 2012 Inc; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10212":"<p><b>Title</b> QUEtiapine / Trimeprazine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Trimeprazine may increase the serum concentration of QUEtiapine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a retrospective analysis of blood samples taken from 1,179 hospitalized patients receiving various doses of quetiapine, treatment with trimeprazine was associated with a 28% increase in the quetiapine concentration-to-dose ratio compared with that of patients who received quetiapine alone.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. <i>J Clin Psychiatry</i>. 2007;68(10):1540-1545. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17960969\">[PubMed 17960969]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10213":"<p><b>Title</b> ARIPiprazole / Trimeprazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimeprazine may increase the serum concentration of ARIPiprazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased aripiprazole effects/toxicities if combined with trimeprazine.</p> \n<p><b>Discussion</b> In a retrospective analysis of 361 blood samples taken from patients receiving various doses of aripiprazole, concomitant treatment with trimeprazine was associated with a 56% increase in the aripiprazole concentration-to-dose ratio compared with that of patients who received aripiprazole alone.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Waade RB, Christensen H, Rudberg I, Refsum H, Hermann M. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. <i>Ther Drug Monit</i>. 2009;31(2):233-238. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19142178\">[PubMed 19142178]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10214":"<p><b>Title</b> Grazoprevir / OATP1B1/SLCO1B1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Grazoprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent administration of grazoprevir with SLCO1B1 (aka OATP1B1) inhibitors is contraindicated.</p>\n<div>\n <p><b>OATP1B1/SLCO1B1 Inhibitors Interacting Members</b> Cobicistat, CycloSPORINE (Systemic), Daclatasvir, Eltrombopag, Gemfibrozil, Glecaprevir and Pibrentasvir, Letermovir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, RifAMPin, Simeprevir, Teriflunomide, Velpatasvir, Voxilaprevir</p>\n</div> \n<p><b>Discussion</b> The grazoprevir AUC was increased by an average of 2- to 15.2-fold with concurrent use of various SLCO1B1 (aka OATP1B1) inhibitors according to data in the elbasvir and grazoprevir prescribing information.<sup>1</sup> With concurrent use of single doses of rifampin, which is both an inhibitor of SLCO1B1 and an inducer of CYP3A4 (which is responsible for metabolism of grazoprevir), the grazoprevir AUC was 8.3- to 10.2-fold higher. With atazanavir/ritonavir (300 mg/100 mg daily) or lopinavir/ritonavir (400 mg/100 mg twice daily) the grazoprevir AUC was 10.6- to 12.9-fold higher. In contrast, concurrent ritonavir alone (100 mg twice daily) with a single dose of grazoprevir was associated with a smaller 2-fold increase in grazoprevir AUC. Cyclosporine (400 mg single dose) had the largest impact on grazoprevir concentrations, as the grazoprevir AUC was 15.2-fold higher. Similarly, concurrent cyclosporine was associated with a 17-fold increase in the grazoprevir maximum serum concentration and a 3.4-fold increase in the grazoprevir minimum serum concentration.<br><br>These drugs appear to increase grazoprevir concentrations primarily via inhibition of SLCO1B1, which is at least partially responsible for hepatic uptake of grazoprevir. <sup>1</sup> By inhibiting this process, less grazoprevir is available for metabolism and elimination. It is also important to note that many SLCO1B1 inhibitors are also capable of at least some CYP3A4 inhibition, which may also contribute to the large magnitude of these interactions as grazoprevir is also a substrate for CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zepatier (elbasvir and grazoprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10215":"<p><b>Title</b> Nivolumab / Immunosuppressants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Management recommendations for this potential interaction differ between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Immunosuppressants may diminish the therapeutic effect of Nivolumab. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of immunosuppressant agents (including systemic corticosteroids) prior to initiation of nivolumab. Use of immunosuppressants after administration of nivolumab (eg, for treatment of immune- related adverse reactions) is unlikely to affect nivolumab efficacy.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Cytarabine (Liposomal), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> The Canadian nivolumab product monograph states that the use of systemic corticosteroids and other immunosuppressants at baseline, prior to initiation of nivolumab, should be avoided because of their potential interference with the pharmacodynamic activity of nivolumab.<sup>1</sup> However, systemic corticosteroids and other immunosuppressants can be used after initiation of nivolumab to treat immune-related adverse reactions. Preliminary results indicate that systemic immunosuppression after starting nivolumab treatment does not appear to preclude response to nivolumab.<sup>1</sup> The US nivolumab prescribing information does not state that immunosuppressant agents should be avoided prior to the initiation of nivolumab, but does note that patients taking immunosuppressants were excluded from clinical trials evaluating the safety and efficacy of nivolumab.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Opdivo (nivolumab) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; February 2016.</p>\n<p>2. Opdivo (nivolumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10216":"<p><b>Title</b> Flecainide / Simeprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Simeprevir may increase the serum concentration of Flecainide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of increased exposure to flecainide, including therapeutic drug monitoring when available, in patients receiving simeprevir.</p> \n<p><b>Discussion</b> Simeprevir US prescribing information recommends flecainide therapeutic drug monitoring, when available, when these agents are used in combination.<sup>1</sup> Flecainide exposure may be increased by concomitant simeprevir according to labeling. The mechanism of this possible interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville NJ: Janssen Products LP; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10217":"<p><b>Title</b> Mexiletine / Simeprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Simeprevir may increase the serum concentration of Mexiletine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of increased mexiletine exposure, including therapeutic drug monitoring when available, in patients receiving simeprevir.</p> \n<p><b>Discussion</b> Simeprevir US prescribing information recommends mexiletine therapeutic drug monitoring, when available, when these agents are used in combination.<sup>1</sup> Mexiletine exposure may be increased by concomitant simeprevir according to labeling. The mechanism of this possible interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville NJ: Janssen Products LP; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10218":"<p><b>Title</b> Propafenone / Simeprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Simeprevir may increase the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of increased propafenone exposure, including therapeutic drug monitoring when available, in patients receiving simeprevir.</p> \n<p><b>Discussion</b> Simeprevir US prescribing information recommends propafenone therapeutic drug monitoring, when available, when these agents are used in combination.<sup>1</sup> Propafenone exposure may be increased by concomitant simeprevir according to labeling. The mechanism of this possible interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville NJ: Janssen Products LP; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10219":"<p><b>Title</b> Simeprevir / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Simeprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of simeprevir and oxcarbazepine.</p> \n<p><b>Discussion</b> Simeprevir US prescribing information states that use with oxcarbazepine is not recommended due to the potential for decreased simeprevir exposure.<sup>1</sup> The suspected primary mechanism of this interaction is oxcarbazepine induction of CYP3A-mediated simeprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville NJ: Janssen Products LP; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10220":"<p><b>Title</b> Simeprevir / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Simeprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of simeprevir and systemic dexamethasone.</p> \n<p><b>Discussion</b> Simeprevir US prescribing information states that use with systemic dexamethasone is not recommended due to the potential for decreased simeprevir exposure.<sup>1</sup> The suspected primary mechanism of this interaction is dexamethasone induction of CYP3A-mediated simeprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville NJ: Janssen Products LP; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10221":"<p><b>Title</b> Simeprevir / Delavirdine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Delavirdine may increase the serum concentration of Simeprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of simeprevir and delavirdine.</p> \n<p><b>Discussion</b> Simeprevir US prescribing information states that use with delavirdine is not recommended due to the potential for increased simeprevir exposure.<sup>1</sup> The suspected primary mechanism of this interaction is delavirdine inhibition of CYP3A-mediated simeprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville NJ: Janssen Products LP; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10222":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Tenoxicam</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tenoxicam may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of tenoxicam together with any other nonsteroidal antiinflammatory drug (NSAID) should be avovided.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Tenoxicam labeling states that the use of tenoxicam together with any other nonsteroidal antiinflammatory drug (NSAID) should be avovided.<sup>1,2,3</sup> This is most likely due to concerns for an increased risk of NSAID-related toxicities with the use of such a combination.<br><br>The mechanism for such an interaction is likely additive toxicity due to overlapping actions from using multiple NSAIDs together.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mobiflex (tenoxicam) [summary of product characteristics]. Bishop's Stortford, United Kingdon: Meda Pharmaceuticals; August 2015.</p>\n<p>2. Tenoxicam [summary of product characteristics]. Egham, Surrey, United Kingdon: Chemidex Pharma Ltd; October 2008.</p>\n<p>3. Tenoxicam [product monograph]. Toronto, Ontario, Canada: AA Pharma Inc; June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10223":"<p><b>Title</b> MiFEPRIStone / Tenoxicam</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: UK tenoxicam labeling recommends avoiding use of tenoxicam for 8 to 12 days after the use of mifepristone. Canadian tenoxicam labeling does not mention this potential interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tenoxicam may diminish the therapeutic effect of MiFEPRIStone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The UK tenoxicam labeling recommends avoiding use for 8 to 12 days after the use of mifepristone due to a potential for decreased mifepristone effectiveness. This potential interaction is not mentioned in Canadian tenoxicam labeling.</p> \n<p><b>Discussion</b> Tenoxicam UK labeling recommends avoiding use for 8 to 12 days after the use of mifepristone due to a potential for nonsteroidal antiinflammatory drugs (NSAIDs), such as tenoxicam, to decrease mifepristone effectiveness.<sup>1,2</sup> The mechanism for this labeled interaction is uncertain, as mifepristone's actions are mediated primarily via antagonism of progesterone and glucocorticoid receptors and not via prostaglandins or related actions. It is possible that this caution is based on the use of mifepristone together with the prostaglandin analog misoprostol. Several studies have reported that NSAIDs do not significantly impair the effectiveness of mifepristone plus misoprostol.<sup>3,4,5</sup> This interaction is not mentioned in Canadian tenoxicam labeling.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mobiflex (tenoxicam) [summary of product characteristics]. Bishop's Stortford, United Kingdon: Meda Pharmaceuticals; August 2015.</p>\n<p>2. Tenoxicam [summary of product characteristics]. Egham, Surrey, United Kingdon: Chemidex Pharma Ltd; October 2008.</p>\n<p>3. Avraham S, Gat I, Duvdevani NR, Haas J, Frenkel Y, Seidman DS. Pre-emptive effect of ibuprofen versus placebo on pain relief and success rates of medical abortion: a double-blind, randomized, controlled study. <i>Fertil Steril</i>. 2012;97(3):612-615. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22265034\">[PubMed 22265034]</a></p>\n<p>4. Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation. <i>Hum Reprod</i>. 2005;20(11):3072-3077. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16055455\">[PubMed 16055455]</a></p>\n<p>5. Radestad A, Bygdeman M. Cervical softening with mifepristone (RU 486) after pretreatment with naproxen. A double-blind randomized study. <i>Contraception</i>. 1992;45(3):221-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1511608\">[PubMed 1511608]</a></p>\n<p>6. Tenoxicam [product monograph]. Toronto, Ontario, Canada: AA Pharma Inc; June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10224":"<p><b>Title</b> Zidovudine / Tenoxicam</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: This interaction is mentioned in UK tenoxicam labeling, but is not mentioned in Canadian tenoxicam labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tenoxicam may enhance the adverse/toxic effect of Zidovudine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The UK tenoxicam labeling recommends caution with this combination due to a possible increased risk for hematologic toxicity. This interaction is not mentioned in the Canadian tenoxicam labeling.</p> \n<p><b>Discussion</b> The UK tenoxicam labeling cautions that there may be an increased risk for hematologic toxicity with concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs), such as tenoxicam, and zidovudine.<sup>1,2</sup> Though no published studies specifically address a possible risk for such toxicities with this combination, there is evidence that several NSAIDs may impair zidovudine metabolism and/or transport and may increase intracellular zidovudine concentrations from both clinical studies<sup>3</sup> and animal studies.<sup>4,5,6,7</sup> In contrast, other clinical and animal studies have reported no significant change in zidovudine pharmacokinetics with concurrent administration of NSAIDs.<sup>8,9,10</sup> This potential interaction is not mentioned in the Canadian tenoxicam labeling.<sup>11</sup><br><br>The specific mechanism for any possible interaction is uncertain, but NSAID inhibition of zidovudine glucuronidation and/or efflux via multidrug resistance protein 4 (MRP4) are possible explanations.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mobiflex (tenoxicam) [summary of product characteristics]. Bishop's Stortford, United Kingdon: Meda Pharmaceuticals; August 2015.</p>\n<p>2. Tenoxicam [summary of product characteristics]. Egham, Surrey, United Kingdon: Chemidex Pharma Ltd; October 2008.</p>\n<p>3. Barry M, Howe J, Back D, et al. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. <i>Br J Clin Pharmacol</i>. 1993;36(1):82-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8373716\">[PubMed 8373716]</a></p>\n<p>4. Clemente MI, Alvarez S, Serramia MJ, et al. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4. <i>Antivir Ther</i>. 2009;14(8):1101-1111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20032540\">[PubMed 20032540]</a></p>\n<p>5. Mano Y, Usui T, Kamimura H. Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes. <i>Drug Metab Dispos</i>. 2007;35(4):602-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267620\">[PubMed 17267620]</a></p>\n<p>6. Mano Y, Usui T, Kamimura H. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2007;63(2):211-216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17200831\">[PubMed 17200831]</a></p>\n<p>7. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. <i>Br J Clin Pharmacol</i>. 1991;32(1):17-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1909542\">[PubMed 1909542]</a></p>\n<p>8. Sahai J, Gallicano K, Garber G, et al. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. <i>Clin Pharmacol Ther</i>. 1992;52(5):464-470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1424420\">[PubMed 1424420]</a></p>\n<p>9. Ragni MV, Miller BJ, Whalen R, Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. <i>Am J Hematol</i>. 1992;40(3):176-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1609771\">[PubMed 1609771]</a></p>\n<p>10. Radwan MA. Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. <i>J Pharm Pharmacol</i>. 2000;52(6):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10875543\">[PubMed 10875543]</a></p>\n<p>11. Tenoxicam [product monograph]. Toronto, Ontario, Canada: AA Pharma Inc; June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10225":"<p><b>Title</b> CarBAMazepine / LevETIRAcetam</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LevETIRAcetam may enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of LevETIRAcetam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for evidence of carbamazepine toxicity with concurrent therapy. Monitor also for evidence of reduced levetiracetam effectiveness.</p> \n<p><b>Discussion</b> A case series describes four patients with severe refractory epilepsy who experienced signs and symptoms consistent with carbamazepine toxicity with concurrent use of levetiracetam and carbamazepine.<sup>1</sup> No changes in carbamazepine or carbamazepine-epoxide concentrations were noted, leading the authors to propose a pharmacodynamic effect. Whether this is mostly additive CNS depressant effects or some other more specific mechanism is uncertain.<br><br>Several studies have concluded that concurrent use of carbamazepine results in a small-to-moderate (ie, 7% to 64%) increase in levetiracetam clearance and/or reductions in levetiracetam concentrations that are of uncertain clinical significance.<sup>2,3,4,5,6,7,8,9</sup> Most of these studies examined enzyme-inducing antiepileptic drugs (EIAEDs) in aggregate, including most often carbamazepine and phenobarbital. The precise impact of carbamazepine versus other EIAEDs is unclear, but as the most widely-represented EIAED in most of these studies, these overall findings are likely at least reasonably representative of carbamazepine's impact. The specific mechanism by which carbamazepine increases levetiracetam clearance is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. <i>Epilepsy Res</i>. 2002;48(3):217-219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11904240\">[PubMed 11904240]</a></p>\n<p>2. Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). <i>Seizure</i>. 2014;23(5):371-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24630809\">[PubMed 24630809]</a></p>\n<p>3. Dahlin MG, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. <i>Pediatr Neurol</i>. 2010;43(4):231-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20837299\">[PubMed 20837299]</a></p>\n<p>4. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. <i>Epilepsia</i>. 2007;48(7):1351-1359. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17573925\">[PubMed 17573925]</a></p>\n<p>5. Fountain NB, Conry JA, Rodriguez-Leyva I, et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. <i>Epilepsy Res</i>. 2007;74(1):60-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17270398\">[PubMed 17270398]</a></p>\n<p>6. Contin M, Albani F, Riva R, Baruzzi A. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. <i>Ther Drug Monit</i>. 2004;26(4):375-379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15257066\">[PubMed 15257066]</a></p>\n<p>7. May TW, Rambeck B, Jurgens U. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. <i>Ther Drug Monit</i>. 2003;25(6):690-699. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14639055\">[PubMed 14639055]</a></p>\n<p>8. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. <i>Epilepsy Res</i>. 2003;53(1-2):47-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12576167\">[PubMed 12576167]</a></p>\n<p>9. Aldaz A, Alzueta N, Viteri C. Influence of comedication on levetiracetam Pharmacokinetics. <i>Ther Drug Monit</i>. 2018;40(1):130-134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29210977\">[PubMed 29210977]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10237":"<p><b>Title</b> Pioglitazone / Clopidogrel</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Clopidogrel may increase the serum concentration of Pioglitazone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients receiving pioglitazone during clopidogrel treatment for evidence of increased pioglitazone effects (eg, decreased blood glucose, evidence of edema or hepatotoxicity).</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, clopidogrel (300 mg single dose on day 1, followed by 75 mg daily on days 2 and 3) increased the pioglitazone (15 mg single dose) AUC 2.1-fold and increased the half-life 1.7-fold (from 6.7 hours to 11 hours).<sup>1</sup> <br><br>The mechanism of this interaction is likely due to clopidogrel inhibition of CYP2C8, an enzyme responsible for pioglitazone metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. <i>Drug Metab Dispos</i>. 2016;44(8):1364-1371. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27260150\">[PubMed 27260150]</a></p>\n<p>2. Actos (pioglitazone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10238":"<p><b>Title</b> MetFORMIN / Ondansetron</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ondansetron may increase the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased metformin effects/toxicities when combined with ondansetron.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, ondansetron (8 mg daily for 5 days) increased the metformin (850 mg single dose) AUC and maximum serum concentration 21% and decreased the metformin renal clearance 36%.<sup>1</sup> The combination of ondansetron and metformin also resulted in significantly lower plasma glucose levels during a 2-hour oral glucose tolerance test compared with metformin alone.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but ondansetron inhibition of multidrug and toxin extrusion (MATE) proteins or organic cation antiporters (OCTs), transporters responsible for the active renal secretion of metformin, may play a role.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Li Q, Yang H, Guo D, et al. Effect of ondansetron on metformin pharmacokinetics and response in healthy subjects. <i>Drug Metab Dispos</i>. 2016;44(4):489-494. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26825640\">[PubMed 26825640]</a></p>\n<p>2. Li Q, Guo D, Dong Z, et al. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). <i>Toxicol Appl Pharmacol</i>. 2013;273(1):100-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24001450\">[PubMed 24001450]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10239":"<p><b>Title</b> Nefopam / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Nefopam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of nefopam to patients who are taking a monoamine oxidase inhibitor.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The nefopam labeling recommends avoiding concurrent use of nefopam with a monoamine oxidase (MAO) inhibitor.<sup>1,2,3</sup> The specific mechanism of this potential interaction is not certain, but since nefopam may work by altering the reuptake of serotonin and other monoamine neurotransmitters,<sup>4</sup> MAO inhibitors may enhance these effects potentially leading to serotonin toxicity and/or other toxic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Acupan (nefopam hydrochloride) [summary of product characteristics]. Takely, United Kingdom: Meda Pharmacuticals Ltd; January 2015.</p>\n<p>2. Acupan (nefopam hydrochloride) [summary of product characteristics]. Gentilly, France: Biocodex; August 2015.</p>\n<p>3. Acupan (nefopam hydrochloride) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200806423. Accessed March 8, 2016.</p>\n<p>4. Evans MS, Lysakowski C, Tramer MR. Nefopam for the prevention of postoperative pain: quantitative systematic review. <i>Br J Anaesth</i>. 2008;101(5):610-617. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18796441\">[PubMed 18796441]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10240":"<p><b>Title</b> Nefopam / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Nefopam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients being treated with nefopam should avoid the ingestion of alcohol-containing beverages and any alcohol-containing medications.</p> \n<p><b>Discussion</b> According to nefopam labeling, patients being treated with nefopam should avoid the ingestion of alcohol-containing beverages and any alcohol-containing medications.<sup>1</sup> The likely mechanism for this potential interaction is additive CNS depressant effects with the combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Acupan (nefopam hydrochloride) [summary of product characteristics]. Gentilly, France: Biocodex; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10241":"<p><b>Title</b> CloZAPine / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erythromycin (Systemic) may enhance the adverse/toxic effect of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased clozapine toxicities (eg, drowsiness, slurred speech, difficulty ambulating, seizure, neutropenia) if combined with erythromycin.</p> \n<p><b>Discussion</b> Three case reports describe signs and symptoms of clozapine toxicity (eg, seizure, drowsiness, slurred speech, disorientation, difficulty ambulating, neutropenia) within a few days of starting erythromycin therapy.<sup>1,2,3</sup> One report documented an elevated serum clozapine concentration of 1,300 mcg/mL 7 days following initiation of erythromycin 250 mg four times daily.<sup>1</sup><br> <br>In contrast, in a study of 12 healthy volunteers, erythromycin (500 mg 9 hours prior to clozapine administration, followed by 1,500 mg per day in divided doses for 2 days) had no significant effect on clozapine pharmacokinetic parameters.<sup>4</sup><br><br>The mechanism of this potential interaction unknown. Erythromycin inhibition of CYP3A4, an enzyme responsible for clozapine metabolism, may play a role. However, because minimal changes in clozapine pharmacokinetics have been observed in combination with the strong CYP3A4 inhibitors ketoconazole, itraconazole, and nefazodone,<sup>5,6,7,8</sup> the role of CYP3A4 inhibition in this potential interaction is questionable.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Funderburg LG, Vertrees JE, Miller AL. Seizure following addition of erythromycin to clozapine treatment. <i>Am J Psychiatry</i>. 1994;151(12):1840-1841. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7977898\">[PubMed 7977898]</a> </p>\n<p>2. Usiskin SI, Nicolson R, Lenane M, Rapoport JL. Retreatment with clozapine after erythromycin-induced neutropenia. <i>Am J Psychiatry</i>. 2000;157(6):1021. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10831491\">[PubMed 10831491]</a></p>\n<p>3. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. <i>Arch Intern Med</i>. 1996;156(6):675-677. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8629881\">[PubMed 8629881]</a></p>\n<p>4. Hagg S, Spigset O, Mjorndal T, Granberg K, Persbo-Lundqvist G, Dahlqvist R. Absence of interaction between erythromycin and a single dose of clozapine. <i>Eur J Clin Pharmacol</i>. 1999;55(3):221-226. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379638\">[PubMed 10379638]</a></p>\n<p>5. Lane HY, Chiu CC, Kazmi Y, et al. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. <i>Drug Metabol Drug Interact</i>. 2001;18(3-4):263-278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11791889\">[PubMed 11791889]</a></p>\n<p>6. Khan AY, Preskorn SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. <i>J Clin Psychiatry</i>. 2001;62(5):375-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11411823\">[PubMed 11411823]</a></p>\n<p>7. Taylor D, Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine plasma concentrations. <i>Int Clin Psychopharmacol</i>. 1999;14(3):185-187. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10435773\">[PubMed 10435773]</a></p>\n<p>8. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole.<i>Eur J Clin Pharmacol</i>. 1998;54(2):167-170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9626923\">[PubMed 9626923]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10242":"<p><b>Title</b> CloZAPine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased clozapine effects/toxicities if combined with strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Serum clozapine concentrations increased 75% in a therapy-stable patient within 2 weeks of initiating nefazodone (200 mg/day for 1 week, then 300 mg/day thereafter).<sup>1</sup> By the end of the second week of concomitant therapy the patient complained of anxiety and dizziness and mild hypotension was noted. Symptoms resolved within 1 week of reducing the dose of nefazodone to 200 mg/day.<sup>1</sup><br><br>In contrast, 6 patients on stable clozapine therapy who were administered nefazodone (100 mg twice daily for 1 week, then 200 mg twice daily for 2 weeks) only had a 4% and 16% increase in clozapine and norclozapine levels, respectively.<sup>2</sup> Additional pharmacokinetics studies also found that ketoconazole and itraconazole had no effect on the pharmacokinetics of clozapine.<sup>3,4</sup><br><br>Clozapine prescribing information states that CYP3A4 inhibitors may increase clozapine levels and lead to adverse reactions.<sup>5</sup> Increased monitoring for clozapine adverse effects is recommended.<sup>5</sup><br><br>Although CYP3A4 is partially responsible for clozapine metabolism, the minimal to negligible changes seen with these strong CYP3A4 inhibitors (ie, nefazodone, ketoconazole, itraconazole) suggests that other enzymes (eg, CYP1A2 or CYP2D6) play a greater role in clozapine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khan AY, Preskorn SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. <i>J Clin Psychiatry</i>. 2001;62(5):375-376. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11411823\">[PubMed 11411823]</a></p>\n<p>2. Taylor D, Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine plasma concentrations. <i>Int Clin Psychopharmacol</i>. 1999;14(3):185-187. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10435773\">[PubMed 10435773]</a></p>\n<p>3. Raaska K, Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. <i>Eur J Clin Pharmacol</i>. 1998;54(2):167-170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9626923\">[PubMed 9626923]</a></p>\n<p>4. Lane HY, Chiu CC, Kazmi Y, et al. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. <i>Drug Metabol Drug Interact</i>. 2001;18(3-4):263-278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11791889\">[PubMed 11791889]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10243":"<p><b>Title</b> Pirfenidone / CYP2C19 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The concomitant use of a strong CYP2C19 inhibitor and pirfenidone should not be used in patients also receiving strong or moderate CYP1A2 inhibitors. No significant interaction is expected when pirfenidone and strong CYP2C19 inhibitors are combined alone.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2C19 Inhibitors (Strong) may increase the serum concentration of Pirfenidone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required if pirfenidone is combined with a strong CYP2C19 inhibitor alone. However, concurrent use of a strong CYP2C19 inhibitor with a strong or moderate CYP1A2 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2C19 Inhibitors (Strong) Interacting Members</b> Fluconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 27 healthy volunteers, coadministration with ciprofloxacin (750 mg twice daily for 6 days) increased pirfenidone (801 mg single dose) exposure by approximately 81%.<sup>1,2</sup> Coadministration with fluvoxamine increased the pirfenidone AUC by approximately 4 fold in healthy nonsmokers and 7 fold in healthy smokers.<sup>1,2</sup><br><br>Pirfenidone is primarily metabolized by CYP1A2, with secondary contribution from other enzymes including CYP2C9, CYP2C19, CYP2D6, and CYP2E1.<sup>1</sup> CYP1A2 is strongly inhibited by both ciprofloxacin and fluvoxamine, although fluvoxamine also inhibits some other enzymes involved in pirfenidone metabolism (most notably CYP2C19). Due to these factors, pirfenidone product labeling recommends avoiding concurrent use of strong or moderate CYP1A2 inhibitors with strong or moderate inhibitors of CYP2C9, CYP2C19, CYP2D6, and/or CYP2E1.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2015.</p>\n<p>2. Esbriet (pirfenidone) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10244":"<p><b>Title</b> Pirfenidone / CYP2C19 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The concomitant use of a moderate CYP2C19 inhibitor and pirfenidone should not be used in patients also receiving strong or moderate CYP1A2 inhibitors. No significant interaction is expected when pirfenidone and moderate CYP2C19 inhibitors are combined alone.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required if pirfenidone is combined with a moderate CYP2C19 inhibitor alone. However, concurrent use of a moderate CYP2C19 inhibitor with a strong or moderate CYP1A2 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2C19 Inhibitors (Moderate) Interacting Members</b> FLUoxetine, FluvoxaMINE, Moclobemide, Stiripentol, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 27 healthy volunteers, coadministration with ciprofloxacin (750 mg twice daily for 6 days) increased pirfenidone (801 mg single dose) exposure by approximately 81%.<sup>1,2</sup> Coadministration with fluvoxamine increased the pirfenidone AUC by approximately 4 fold in healthy nonsmokers and 7 fold in healthy smokers.<sup>1,2</sup><br><br>Pirfenidone is primarily metabolized by CYP1A2, with secondary contribution from other enzymes including CYP2C9, CYP2C19, CYP2D6, and CYP2E1.<sup>1</sup> CYP1A2 is strongly inhibited by both ciprofloxacin and fluvoxamine, although fluvoxamine also inhibits some other enzymes involved in pirfenidone metabolism (most notably CYP2C19). Due to these factors, pirfenidone product labeling recommends avoiding concurrent use of strong or moderate CYP1A2 inhibitors with strong or moderate inhibitors of CYP2C9, CYP2C19, CYP2D6, and/or CYP2E1.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2015.</p>\n<p>2. Esbriet (pirfenidone) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10246":"<p><b>Title</b> Pirfenidone / CYP2C9 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The concomitant use of a moderate CYP2C9 inhibitor and pirfenidone should not be used in patients also receiving strong or moderate CYP1A2 inhibitors. No significant interaction is expected when pirfenidone and moderate CYP2C9 inhibitors are combined alone.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required if pirfenidone is combined with a moderate CYP2C9 inhibitor alone. However, concurrent use of a moderate CYP2C9 inhibitor with a strong or moderate CYP1A2 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2C9 Inhibitors (Moderate) Interacting Members</b> Fluconazole, MiFEPRIStone</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 27 healthy volunteers, coadministration with ciprofloxacin (750 mg twice daily for 6 days) increased pirfenidone (801 mg single dose) exposure by approximately 81%.<sup>1,2</sup> Coadministration with fluvoxamine increased the pirfenidone AUC by approximately 4 fold in healthy nonsmokers and 7 fold in healthy smokers.<sup>1,2</sup><br><br>Pirfenidone is primarily metabolized by CYP1A2, with secondary contribution from other enzymes including CYP2C9, CYP2C19, CYP2D6, and CYP2E1.<sup>1</sup> CYP1A2 is strongly inhibited by both ciprofloxacin and fluvoxamine, although fluvoxamine also inhibits some other enzymes involved in pirfenidone metabolism (most notably CYP2C19). Due to these factors, pirfenidone product labeling recommends avoiding concurrent use of strong or moderate CYP1A2 inhibitors with strong or moderate inhibitors of CYP2C9, CYP2C19, CYP2D6, and/or CYP2E1.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2015.</p>\n<p>2. Esbriet (pirfenidone) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10247":"<p><b>Title</b> Pirfenidone / CYP2D6 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The concomitant use of a strong CYP2D6 inhibitor and pirfenidone should not be used in patients also receiving strong or moderate CYP1A2 inhibitors. No significant interaction is expected when pirfenidone and strong CYP2D6 inhibitors are combined alone.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pirfenidone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required if pirfenidone is combined with a strong CYP2D6 inhibitor alone. However, concurrent use of a strong CYP2D6 inhibitor with a strong or moderate CYP1A2 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 27 healthy volunteers, coadministration with ciprofloxacin (750 mg twice daily for 6 days) increased pirfenidone (801 mg single dose) exposure by approximately 81%.<sup>1,2</sup> Coadministration with fluvoxamine increased the pirfenidone AUC by approximately 4 fold in healthy nonsmokers and 7 fold in healthy smokers.<sup>1,2</sup><br><br>Pirfenidone is primarily metabolized by CYP1A2, with secondary contribution from other enzymes including CYP2C9, CYP2C19, CYP2D6, and CYP2E1.<sup>1</sup> CYP1A2 is strongly inhibited by both ciprofloxacin and fluvoxamine, although fluvoxamine also inhibits some other enzymes involved in pirfenidone metabolism (most notably CYP2C19). Due to these factors, pirfenidone product labeling recommends avoiding concurrent use of strong or moderate CYP1A2 inhibitors with strong or moderate inhibitors of CYP2C9, CYP2C19, CYP2D6, and/or CYP2E1.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2015.</p>\n<p>2. Esbriet (pirfenidone) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10248":"<p><b>Title</b> Pirfenidone / CYP2D6 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The concomitant use of a moderate CYP2D6 inhibitor and pirfenidone should not be used in patients also receiving strong or moderate CYP1A2 inhibitors. No significant interaction is expected when pirfenidone and moderate CYP2D6 inhibitors are combined alone.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required if pirfenidone is combined with a moderate CYP2D6 inhibitor alone. However, concurrent use of a moderate CYP2D6 inhibitor with a strong or moderate CYP1A2 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 27 healthy volunteers, coadministration with ciprofloxacin (750 mg twice daily for 6 days) increased pirfenidone (801 mg single dose) exposure by approximately 81%.<sup>1,2</sup> Coadministration with fluvoxamine increased the pirfenidone AUC by approximately 4 fold in healthy nonsmokers and 7 fold in healthy smokers.<sup>1,2</sup><br><br>Pirfenidone is primarily metabolized by CYP1A2, with secondary contribution from other enzymes including CYP2C9, CYP2C19, CYP2D6, and CYP2E1.<sup>1</sup> CYP1A2 is strongly inhibited by both ciprofloxacin and fluvoxamine, although fluvoxamine also inhibits some other enzymes involved in pirfenidone metabolism (most notably CYP2C19). Due to these factors, pirfenidone product labeling recommends avoiding concurrent use of strong or moderate CYP1A2 inhibitors with strong or moderate inhibitors of CYP2C9, CYP2C19, CYP2D6, and/or CYP2E1.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2015.</p>\n<p>2. Esbriet (pirfenidone) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10249":"<p><b>Title</b> Pirfenidone / CYP2E1 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The concomitant use of a strong CYP2E1 inhibitor and pirfenidone should not be used in patients also receiving strong or moderate CYP1A2 inhibitors. No significant interaction is expected when pirfenidone and strong CYP2E1 inhibitors are combined alone.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2E1 Inhibitors (Strong) may increase the serum concentration of Pirfenidone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required if pirfenidone is combined with a strong CYP2E1 inhibitor alone. However, concurrent use of a strong CYP2E1 inhibitor with a strong or moderate CYP1A2 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2E1 Inhibitors (Strong) Interacting Members</b> Disulfiram</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 27 healthy volunteers, coadministration with ciprofloxacin (750 mg twice daily for 6 days) increased pirfenidone (801 mg single dose) exposure by approximately 81%.<sup>1,2</sup> Coadministration with fluvoxamine increased the pirfenidone AUC by approximately 4 fold in healthy nonsmokers and 7 fold in healthy smokers.<sup>1,2</sup><br><br>Pirfenidone is primarily metabolized by CYP1A2, with secondary contribution from other enzymes including CYP2C9, CYP2C19, CYP2D6, and CYP2E1.<sup>1</sup> CYP1A2 is strongly inhibited by both ciprofloxacin and fluvoxamine, although fluvoxamine also inhibits some other enzymes involved in pirfenidone metabolism (most notably CYP2C19). Due to these factors, pirfenidone product labeling recommends avoiding concurrent use of strong or moderate CYP1A2 inhibitors with strong or moderate inhibitors of CYP2C9, CYP2C19, CYP2D6, and/or CYP2E1.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2015.</p>\n<p>2. Esbriet (pirfenidone) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10250":"<p><b>Title</b> Pirfenidone / CYP2E1 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The concomitant use of a moderate CYP2E1 inhibitor and pirfenidone should not be used in patients also receiving strong or moderate CYP1A2 inhibitors. No significant interaction is expected when pirfenidone and moderate CYP2E1 inhibitors are combined alone.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP2E1 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required if pirfenidone is combined with a moderate CYP2E1 inhibitor alone. However, concurrent use of a moderate CYP2E1 inhibitor with a strong or moderate CYP1A2 inhibitor should be avoided.</p>\n<div>\n <p><b>CYP2E1 Inhibitors (Moderate) Interacting Members</b> Chlormethiazole, Isoniazid</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 27 healthy volunteers, coadministration with ciprofloxacin (750 mg twice daily for 6 days) increased pirfenidone (801 mg single dose) exposure by approximately 81%.<sup>1,2</sup> Coadministration with fluvoxamine increased the pirfenidone AUC by approximately 4 fold in healthy nonsmokers and 7 fold in healthy smokers.<sup>1,2</sup><br><br>Pirfenidone is primarily metabolized by CYP1A2, with secondary contribution from other enzymes including CYP2C9, CYP2C19, CYP2D6, and CYP2E1.<sup>1</sup> CYP1A2 is strongly inhibited by both ciprofloxacin and fluvoxamine, although fluvoxamine also inhibits some other enzymes involved in pirfenidone metabolism (most notably CYP2C19). Due to these factors, pirfenidone product labeling recommends avoiding concurrent use of strong or moderate CYP1A2 inhibitors with strong or moderate inhibitors of CYP2C9, CYP2C19, CYP2D6, and/or CYP2E1.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Esbriet (pirfenidone) [prescribing information]. South San Francisco, CA: Genentech USA Inc; September 2015.</p>\n<p>2. Esbriet (pirfenidone) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10251":"<p><b>Title</b> CYP2B6 Substrates (High risk with Inducers) / Nilotinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nilotinib may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effect/therapeutic failure of CYP2B6 substrates (or increased effects if CYP2B6 is responsible for conversion of a prodrug to its active metabolite [eg, cyclophosphamide]) if combined with nilotinib.</p>\n<div>\n <p><b>CYP2B6 Substrates (High risk with Inducers) Interacting Members</b> BuPROPion, Cyclophosphamide, Efavirenz, Ifosfamide, Methadone, Selegiline, Velpatasvir</p>\n</div> \n<p><b>Discussion</b> Nilotinib prescribing information states that concomitant use of CYP2B6 substrates and nilotinib may lead to decreased efficacy of the CYP2B6 substrate.<sup>1</sup> In vitro data indicate that nilotinib may induce CYP2B6,<sup>1</sup> but no studies have been conducted to assess the potential for nilotinib to decrease serum concentrations of CYP2B6 substrates in humans.<sup>1</sup> Monitoring for decreased effects and therapeutic failure of CYP2B6 substrates is recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10252":"<p><b>Title</b> CYP2B6 Substrates (High risk with Inducers) / CYP2B6 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2B6 Inducers (Moderate) may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of the CYP substrates listed in this monograph if a CYP inducer is initiated/dose increased, and for increased effects if a CYP inducer is discontinued/dose decreased (note that the opposite effects are expected for some inactive prodrugs).</p>\n<div>\n <p><b>CYP2B6 Substrates (High risk with Inducers) Interacting Members</b> BuPROPion, Cyclophosphamide, Efavirenz, Ifosfamide, Methadone, Selegiline, Velpatasvir</p>\n <p><b>CYP2B6 Inducers (Moderate) Interacting Members</b> CarBAMazepine, Efavirenz, Nevirapine, RifAMPin, Ritonavir</p>\n</div> \n<p><b>Discussion</b> The CYP inducers listed in this monograph will probably increase the metabolism of the substrates of this pathway. Substrate clearance would increase and serum concentrations would decrease. Decreased effects of the substrates are expected (note that the opposite effect is expected for some inactive prodrugs).<br><br>CYP substrates are included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant decrease in serum concentration of the substrate (ie, more than 50%) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inducers have been labeled “moderate” because they have been shown to cause significant increases in CYP activity, and, as a result, significant increases in the clearance of drugs metabolized by this pathway.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. <i>J Clin Pharmacol</i>. 2003;43(5):443-469. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p>2. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry: Drug Interaction Studies -- Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf. Published February 2012. Accessed March 18, 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10253":"<p><b>Title</b> Thyroid Products / Furosemide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This is likely of clinical relevance only at higher furosemide doses (more than 80 mg).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Furosemide may decrease the protein binding of Thyroid Products. This may lead to a transient increase in free thyroid hormone concentrations and to a later decrease in total thyroid hormone concentrations. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> Furosemide displaced thyroxine (T4) from thyroxine binding globulin (TBG) in a study of 5 patients on peritoneal dialysis who were given a single 500 mg dose of furosemide.<sup>1</sup> This finding was confirmed in another study of 4 patients with severe non-thyroid-related illness.<sup>2</sup> Furosemide prescribing information warns that high doses (more than 80 mg) may transiently increase free thyroid hormone concentrations, which may lead to a later decrease in total thyroid concentrations.<sup>3</sup><br><br>It appears that furosemide binds to the same site on TBG as does thyroxine. The clinical significance of this apparent interaction is unclear. Furosemide may impair the accuracy of free T4 assays and thus lead to problems with diagnosis and laboratory monitoring of thyroid disorders.<sup>4</sup> Broader clinical implications of such transiently elevated free T4 concentrations have not been studied. These effects appear to be dose dependent and relatively short-lived given the quick elimination of furosemide. Separating the administration of furosemide from the sample collection for a free T4 assay may lessen the impact of this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stockigt JR, Lim CF, Barlow JW, et al. Interaction of furosemide with serum thyroxine-binding sites: in vivo and in vitro studies and comparison with other inhibitors. <i>J Clin Endocrinol Metab</i>. 1985;60(5):1025-1031. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2579968\">[PubMed 2579968]</a></p>\n<p>2. Stockigt JR, Lim CF, Barlow JW, Stevens V, Topliss DJ, Wynne KN. High concentrations of furosemide inhibit serum binding of thyroxine. <i>J Clin Endocrinol Metab</i>. 1984;59(1):62-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6725526\">[PubMed 6725526]</a></p>\n<p>3. Lasix (furosemide) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; March 2016.</p>\n<p>4. Christofides ND. Furosemide interference in newer free thyroxine assays. <i>Clin Chem</i>. 1999;45(8 Pt 1):1315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10430826\">[PubMed 10430826]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10254":"<p><b>Title</b> Serotonin Modulators / Opioid Analgesics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, mental status changes, autonomic instability, neuromuscular hyperactivity) when opioid analgesics are combined with serotonin modulators. If symptoms of serotonin syndrome develop, discontinuation of both the opioid analgesic and the serotonin modulator is recommended.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, Tedizolid, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> The US Food and Drug Administration (FDA) issued a drug safety communication warning that opioid analgesics may interact with serotonergic medications and lead to the development of serotonin syndrome.<sup>1</sup> Cases of serotonin syndrome in the FDA Adverse Event Reporting System (FAERS) database were reported most frequently with fentanyl and methadone, but were also reported with other opioids.<sup>1</sup> The labels of all opioid analgesics will be updated to include information about serotonin syndrome.<sup>1</sup><br><br>In addition to cases of serotonin syndrome reported in the FAERS database, numerous cases have been published that implicate opioid analgesics as a contributing factor in the development of serotonin syndrome. The majority of published reports describe patients who developed serotonin syndrome while taking one or more serotonin modulators along with tramadol,<sup>2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19</sup> fentanyl,<sup>20,21,22,23,24,25,26,27,28,29,30</sup> meperidine,<sup>31,32,33,34,35,36,37,38</sup> or methadone.<sup>39,40,41</sup> Cases have also been reported when serotonin modulators were combined with oxycodone,<sup>7,42,43,44,45</sup> morphine,<sup>46,47</sup> remifentanil,<sup>48,49</sup> codeine,<sup>50</sup> hydromorphone,<sup>51</sup> buprenorphine,<sup>52</sup> or pentazocine.<sup>53</sup> Other reports describe the development of serotonin syndrome with opioid use alone, either with combinations of opioid analgesics or in overdose, in the absence of serotonin modulator therapy.<sup>54,55,56,57,58,59</sup> <br><br>The mechanism of these interactions is likely related to additive effects on serotonin. Opioids may increase serotonin effects via direct serotonin receptor stimulation or by inhibition of serotonin reuptake.<sup>57,60</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm. Published March 22, 2016. Accessed March 24, 2016.</p>\n<p>2. Egberts AC, ter Borgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. <i>Int Clin Psychopharmacol</i>. 1997;12(3):181-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9248876\">[PubMed 9248876]</a></p>\n<p>3. Lantz MS, Buchalter EN, Giambanco V. Serotonin syndrome following the administration of tramadol with paroxetine. <i>Int J Geriatr Psychiatry</i>. 1998;13(5):343-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9658268\">[PubMed 9658268]</a></p>\n<p>4. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. <i>Ann Pharmacother</i>. 1997;31(2):175-177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9034418\">[PubMed 9034418]</a></p>\n<p>5. Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. <i>J Clin Psychopharmacol</i>. 2015;35(4):382-388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26082973\">[PubMed 26082973]</a></p>\n<p>6. Shakoor M, Ayub S, Ahad A, Ayub Z. Transient serotonin syndrome cause by concurrent use of tramadol and selective serotonin reuptake inhibitor. <i>Am J Case Rep</i>. 2014;15:562-564. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25540831\">[PubMed 25540831]</a></p>\n<p>7. Falls BA, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2014;55(3):305-309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>8. El-Okdi NS, Lumbrezer D, Karanovic D, Ghose A, Assaly R. Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. <i>Am J Ther</i>. 2014;21(4):e97-e99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24158007\">[PubMed 24158007]</a></p>\n<p>9. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>10. Lamberg JJ, Gordin VN. Serotonin syndrome in a patient with chronic pain polypharmacy. <i>Pain Med</i>. 2014;15(8):1429-1431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22925399\">[PubMed 22925399]</a></p>\n<p>11. Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. <i>Age Ageing</i>. 2011;40(4):528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21414947\">[PubMed 21414947]</a></p>\n<p>12. John AP, Koloth R. Severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine. <i>Aust N Z J Psychiatry</i>. 2007;41(2):192-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17484083\">[PubMed 17484083]</a></p>\n<p>13. Kitson R, Carr B. Tramadol and severe serotonin syndrome. <i>Anaesthesia</i>. 2005;60(9):934-935. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16115263\">[PubMed 16115263]</a></p>\n<p>14. Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration. <i>Clin Neuropharmacol</i>. 2004;27(3):150-151. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15190240\">[PubMed 15190240]</a></p>\n<p>15. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. <i>Am J Psychiatry</i>. 2004;161(6):1129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15169709\">[PubMed 15169709]</a></p>\n<p>16. Venlafaxine and tramadol: serotonin syndrome. <i>Prescrire Int</i>. 2004;13(70):57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15148976\">[PubMed 15148976]</a></p>\n<p>17. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. <i>Ann Pharmacother</i>. 2004;38(3):411-413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14970364\">[PubMed 14970364]</a></p>\n<p>18. Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. <i>J Clin Psychopharmacol</i>. 2002;22(4):440-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12172351\">[PubMed 12172351]</a></p>\n<p>19. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. <i>J R Soc Med</i>. 1999;92(9):474-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10645303\">[PubMed 10645303]</a></p>\n<p>20. Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J. Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy. <i>J Clin Anesth</i>. 2015;27(3):247-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25499271\">[PubMed 25499271]</a></p>\n<p>21. Pedavally S, Fugate JE, Rabinstein AA. Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. <i>Neurocrit Care</i>. 2014;21(1):108-113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24052457\">[PubMed 24052457]</a></p>\n<p>22. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>23. Alkhatib AA, Peterson KA, Tuteja AK. Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy. <i>Dig Dis Sci</i>. 2010;55(1):215-216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19165596\">[PubMed 19165596]</a></p>\n<p>24. Kirschner R, Donovan JW. Serotonin syndrome precipitated by fentanyl during procedural sedation. <i>J Emerg Med</i>. 2010;38(4):477-480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18757161\">[PubMed 18757161]</a></p>\n<p>25. Rang ST, Field J, Irving C. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. <i>Can J Anaesth</i>. 2008;55(8):521-525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18676387\">[PubMed 18676387]</a></p>\n<p>26. Ozkardesler S, Gurpinar T, Akan M, et al. A possible perianesthetic serotonin syndrome related to intrathecal fentanyl. <i>J Clin Anesth</i>. 2008;20(2):143-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18410872\">[PubMed 18410872]</a></p>\n<p>27. Ailawadhi S, Sung KW, Carlson LA, Baer MR. Serotonin syndrome caused by interaction between citalopram and fentanyl. <i>J Clin Pharm Ther</i>. 2007;32(2):199-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17381671\">[PubMed 17381671]</a></p>\n<p>28. Roy S, Fortier LP. Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafaxine. <i>Can J Anaesth</i>. 2003;50(1):32-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12514147\">[PubMed 12514147]</a></p>\n<p>29. Noble WH, Baker A. MAO inhibitors and coronary artery surgery: a patient death. <i>Can J Anaesth</i>. 1992;39(10):1061-1066. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1464133\">[PubMed 1464133]</a></p>\n<p>30. Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ. Cardiac surgery in a patient taking monoamine oxidase inhibitors: an adverse fentanyl reaction. <i>Anesth Analg</i>. 1994;78(3):593-597. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8109782\">[PubMed 8109782]</a></p>\n<p>31. Asch DA, Parker RM. The Libby Zion case. One step forward or two steps backward? <i>N Engl J Med</i>. 1988;318(12):771-775. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3347226\">[PubMed 3347226]</a></p>\n<p>32. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. <i>Lancet</i>. 1991;337(8735):246. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1670882\">[PubMed 1670882]</a></p>\n<p>33. Das PK, Warkentin DI, Hewko R, Forrest DL. Serotonin syndrome after concomitant treatment with linezolid and meperidine. <i>Clin Infect Dis</i>. 2008;46(2):264-265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18171260\">[PubMed 18171260]</a></p>\n<p>34. Altman EM, Manos GH. Serotonin syndrome associated with citalopram and meperidine. <i>Psychosomatics</i>. 2007;48(4):361-363. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17600178\">[PubMed 17600178]</a></p>\n<p>35. Tissot TA. Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use. <i>Anesthesiology</i>. 2003;98(6):1511-1512. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12766667\">[PubMed 12766667]</a></p>\n<p>36. Dougherty JA, Young H, Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine. <i>Ann Pharmacother</i>. 2002;36(10):1647-1648. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12243617\">[PubMed 12243617]</a></p>\n<p>37. Meyer D, Halfin V. Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review. <i>J Clin Psychopharmacol</i>. 1981;1(5):319-321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7334144\">[PubMed 7334144]</a></p>\n<p>38. Gillman PK. Possible serotonin syndrome with moclobemide and pethidine. <i>Med J Aust</i>. 1995;162(10):554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7776924\">[PubMed 7776924]</a></p>\n<p>39. Lee J, Franz L, Goforth HW. Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. <i>Psychosomatics</i>. 2009;50(6):638-639. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19996237\">[PubMed 19996237]</a></p>\n<p>40. Martinez TT, Martinez DN. A case of serotonin syndrome associated with methadone overdose. <i>Proc West Pharmacol Soc</i>. 2008;51:42-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19544673\">[PubMed 19544673]</a></p>\n<p>41. Bush E, Miller C, Friedman I. A case of serotonin syndrome and mutism associated with methadone. <i>J Palliat Med</i>. 2006;9(6):1257-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17187532\">[PubMed 17187532]</a></p>\n<p>42. Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. <i>Ann Pharmacother</i>. 2006;40(1):155-157. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368927\">[PubMed 16368927]</a></p>\n<p>43. Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB. Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? <i>J Am Med Dir Assoc</i>. 2005;6(4):265-269. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16005413\">[PubMed 16005413]</a></p>\n<p>44. Song HK. Serotonin syndrome with perioperative oxycodone and pregabalin. <i>Pain Physician</i>. 2013;16(5):e632-e633. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24077214\">[PubMed 24077214]</a></p>\n<p>45. Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. <i>J Clin Pharmacol</i>. 2001;41(2):224-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11210406\">[PubMed 11210406]</a></p>\n<p>46. Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H. Serotonin syndrome probably triggered by a morphine-phenelzine interaction. <i>Pharmacotherapy</i>. 2015;35(6):e102-e105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25903219\">[PubMed 25903219]</a></p>\n<p>47. Brown TM, Skop BP. Nitroglycerin in the treatment of the serotonin syndrome. <i>Ann Pharmacother</i>. 1996;30(2):191-192. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8835057\">[PubMed 8835057]</a></p>\n<p>48. Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE. Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil. <i>J Clin Anesth</i>. 2013;25(1):52-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23391344\">[PubMed 23391344]</a></p>\n<p>49. Hunter B, Kleinert MM, Osatnik J, Soria E. Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil? <i>Anesth Analg</i>. 2006;102(5):1589. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16632855\">[PubMed 16632855]</a></p>\n<p>50. Filter ER, Gorczynski L, Fernandes JR. Fatal intoxication with a selective serotonin reuptake inhibitor, lorazepam, and codeine. <i>Am J Forensic Med Pathol</i>. 2007;28(4):361-363. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18043028\">[PubMed 18043028]</a></p>\n<p>51. Fluoxetine and hydromorphone: serotonin syndrome? <i>Prescrire Int</i>. 2004;13(70):57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15148975\">[PubMed 15148975]</a></p>\n<p>52. Isenberg D, Wong SC, Curtis JA. Serotonin syndrome triggered by a single dose of suboxone. <i>Am J Emerg Med</i>. 2008;26(7):840.e3-840.e5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18774063\">[PubMed 18774063]</a></p>\n<p>53. Hansen TE, Dieter K, Keepers GA. Interaction of fluoxetine and pentazocine. <i>Am J Psychiatry</i>. 1990;147(7):949-950. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2356884\">[PubMed 2356884]</a></p>\n<p>54. Marechal C, Honorat R, Claudet I. Serotonin syndrome induced by tramadol intoxication in an 8-month-old infant. <i>Pediatr Neurol</i>. 2011;44(1):72-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21147393\">[PubMed 21147393]</a></p>\n<p>55. Tashakori A, Afshari R. Tramadol overdose as a cause of serotonin syndrome: a case series. <i>Clin Toxicol (Phila)</i>. 2010;48(4):337-341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20367390\">[PubMed 20367390]</a></p>\n<p>56. Vizcaychipi MP, Walker S, Palazzo M. Serotonin syndrome triggered by tramadol. <i>Br J Anaesth</i>. 2007;99(6):919. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18006535\">[PubMed 18006535]</a></p>\n<p>57. Hillman AD, Witenko CJ, Sultan SM, Gala G. Serotonin syndrome caused by fentanyl and methadone in a burn injury. <i>Pharmacotherapy</i>. 2015;35(1):112-117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25615513\">[PubMed 25615513]</a></p>\n<p>58. Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL. Meperidine-induced serotonin syndrome in a susceptible patient. <i>Br J Anaesth</i>. 2009;103(3):369-370. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19556270\">[PubMed 19556270]</a></p>\n<p>59. Robles LA. Serotonin syndrome induced by fentanyl in a child: case report. <i>Clin Neuropharmacol</i>. 2015;38(5):206-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26366964\">[PubMed 26366964]</a></p>\n<p>60. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>Br J Anaesth</i>. 2005;95(4):434-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16051647\">[PubMed 16051647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10255":"<p><b>Title</b> TraMADol / Serotonin Modulators</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, mental status changes, autonomic instability, neuromuscular hyperactivity) and/or seizures when tramadol is combined with serotonin modulators. Canadian tramadol labeling lists use with monoamine oxidase inhibitors (or within 14 days of such therapy) as contraindicated.</p>\n<div>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, Tedizolid, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> Numerous case reports implicate tramadol as a contributing factor in the development of serotonin syndrome. The majority of published reports describe patients who developed serotonin syndrome while taking one or more serotonin modulators along with tramadol.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19</sup> Other reports describe the development of serotonin syndrome in cases of tramadol overdose.<sup>20,21</sup><br><br>The US tramadol prescribing information states that concomitant use of tramadol with serotonin modulators may increase the risk for both serotonin syndrome and seizures.<sup>22</sup> Careful monitoring for both adverse events is recommended if serotonin modulators are combined with tramadol.<sup>22</sup> Canadian tramadol labeling lists use with monoamine oxidase inhibitors (or within 14 days of such therapy) as contraindicated.<sup>23</sup> <br><br>Because tramadol is thought to be a weak serotonin reuptake inhibitor, the mechanism of these interactions is likely related to additive effects on serotonin.<sup>24,25</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Egberts AC, ter Borgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. <i>Int Clin Psychopharmacol</i>. 1997;12(3):181-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9248876\">[PubMed 9248876]</a></p>\n<p>2. Lantz MS, Buchalter EN, Giambanco V. Serotonin syndrome following the administration of tramadol with paroxetine. <i>Int J Geriatr Psychiatry</i>. 1998;13(5):343-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9658268\">[PubMed 9658268]</a></p>\n<p>3. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. <i>Ann Pharmacother</i>. 1997;31(2):175-177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9034418\">[PubMed 9034418]</a></p>\n<p>4. Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. <i>J Clin Psychopharmacol</i>. 2015;35(4):382-388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26082973\">[PubMed 26082973]</a></p>\n<p>5. Shakoor M, Ayub S, Ahad A, Ayub Z. Transient serotonin syndrome cause by concurrent use of tramadol and selective serotonin reuptake inhibitor. <i>Am J Case Rep</i>. 2014;15:562-564. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25540831\">[PubMed 25540831]</a></p>\n<p>6. Falls BA, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2014;55(3):305-309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>7. El-Okdi NS, Lumbrezer D, Karanovic D, Ghose A, Assaly R. Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. <i>Am J Ther</i>. 2014;21(4):e97-e99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24158007\">[PubMed 24158007]</a></p>\n<p>8. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>9. Lamberg JJ, Gordin VN. Serotonin syndrome in a patient with chronic pain polypharmacy. <i>Pain Med</i>. 2014;15(8):1429-1431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22925399\">[PubMed 22925399]</a></p>\n<p>10. Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. <i>Age Ageing</i>. 2011;40(4):528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21414947\">[PubMed 21414947]</a></p>\n<p>11. John AP, Koloth R. Severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine. <i>Aust N Z J Psychiatry</i>. 2007;41(2):192-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17484083\">[PubMed 17484083]</a></p>\n<p>12. Kitson R, Carr B. Tramadol and severe serotonin syndrome. <i>Anaesthesia</i>. 2005;60(9):934-935. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16115263\">[PubMed 16115263]</a></p>\n<p>13. Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration. <i>Clin Neuropharmacol</i>. 2004;27(3):150-151. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15190240\">[PubMed 15190240]</a></p>\n<p>14. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. <i>Am J Psychiatry</i>. 2004;161(6):1129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15169709\">[PubMed 15169709]</a></p>\n<p>15. Venlafaxine and tramadol: serotonin syndrome. <i>Prescrire Int</i>. 2004;13(70):57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15148976\">[PubMed 15148976]</a></p>\n<p>16. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. <i>Ann Pharmacother</i>. 2004;38(3):411-413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14970364\">[PubMed 14970364]</a></p>\n<p>17. Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. <i>J Clin Psychopharmacol</i>. 2002;22(4):440-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12172351\">[PubMed 12172351]</a></p>\n<p>18. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. <i>J R Soc Med</i>. 1999;92(9):474-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10645303\">[PubMed 10645303]</a></p>\n<p>19. Vizcaychipi MP, Walker S, Palazzo M. Serotonin syndrome triggered by tramadol. <i>Br J Anaesth</i>. 2007;99(6):919. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18006535\">[PubMed 18006535]</a></p>\n<p>20. Marechal C, Honorat R, Claudet I. Serotonin syndrome induced by tramadol intoxication in an 8-month-old infant. <i>Pediatr Neurol</i>. 2011;44(1):72-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21147393\">[PubMed 21147393]</a></p>\n<p>21. Tashakori A, Afshari R. Tramadol overdose as a cause of serotonin syndrome: a case series. <i>Clin Toxicol (Phila)</i>. 2010;48(4):337-341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20367390\">[PubMed 20367390]</a></p>\n<p>22. Ultram (tramadol) [prescribing information]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc; September 2009.</p>\n<p>23. Durela (tramadol) [product monograph]. Mississauga, Ontario, Canada: Cipher Pharmaceuticals Inc; May 2014.</p>\n<p>24. Hillman AD, Witenko CJ, Sultan SM, Gala G. Serotonin syndrome caused by fentanyl and methadone in a burn injury. <i>Pharmacotherapy</i>. 2015;35(1):112-117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25615513\">[PubMed 25615513]</a></p>\n<p>25. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>Br J Anaesth</i>. 2005;95(4):434-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16051647\">[PubMed 16051647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10256":"<p><b>Title</b> Lomitapide / Ethinyl Estradiol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ethinyl Estradiol may increase the serum concentration of Lomitapide. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients taking lomitapide 5 mg daily may continue the same dosage. Patients taking lomitapide 10 mg daily or more should decrease the dose of lomitapide by half when used in combination with any oral contraceptive. The dose of lomitapide may then be up-titrated to a maximum adult dose of 40 mg daily.</p> \n<p><b>Discussion</b> The lomitapide maximum serum concentration and AUC were increased by approximately 1.4- and 1.3-fold, respectively, in a clinical study where subjects received ethinyl estradiol/norgestimate (0.035 mg/0.25 mg daily for 6 days) together with lomitapide (20 mg daily).<sup>1,2</sup><br><br>The likely mechanism for this interaction is ethinyl estradiol inhibition of the CYP3A4-mediated metabolism of lomitapide. Ethinyl estradiol has been shown to have relatively minimial CYP3A4 inhibition, increasing the AUC of other known CYP3A4 substrates by only an average of 21% or less.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; March 2016.</p>\n<p>2. Patel G, King A, Dutta S, et al. Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. <i>J Clin Pharmacol</i>. 2016;56(1):47-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26120010\">[PubMed 26120010]</a></p>\n<p>3. Edelman A, Munar M, Elman MR, Koop D, Cherala G. Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. <i>Br J Clin Pharmacol</i>. 2012;74(3):510-514. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22299599\">[PubMed 22299599]</a></p>\n<p>4. Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. <i>Br J Clin Pharmacol</i>. 2000;50(4):333-337. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11012556\">[PubMed 11012556]</a></p>\n<p>5. Balogh A, Gessinger S, Svarovsky U, et al. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans? <i>Eur J Clin Pharmacol</i>. 1998;54(9-10):729-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9923576\">[PubMed 9923576]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10257":"<p><b>Title</b> Melatonin / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Melatonin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider the use of alternative agents in order to avoid this combination. If combined, monitor for increased melatonin effects (eg, sedation, somnolence) if combined with fluvoxamine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 5 healthy volunteers, fluvoxamine (50 mg single dose) increased the melatonin (5 mg single dose) AUC and maximum serum concentration 23-fold and 12-fold, respectively.<sup>1</sup> While not a primary outcome of the study, the authors did note that all volunteers reported remarkable drowsiness after melatonin intake that was even more pronounced after fluvoxamine coadministration.<sup>1</sup><br><br>The mechanism of this interaction is likely due to fluvoxamine inhibition of melatonin metabolism, mostly through inhibition of CYP1A2, but inhibition of CYP2C19 or CYP2C9 may also play a role.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hartter S, Grozinger M, Weigmann H, Roschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. <i>Clin Pharmacol Ther</i>. 2000;67(1):1-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10668847\">[PubMed 10668847]</a></p>\n<p>2. Facciola G, Hidestrand M, von Bahr C, Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2001;56(12):881-888. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11317475\">[PubMed 11317475]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10258":"<p><b>Title</b> Moclobemide / TraMADol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> TraMADol may enhance the serotonergic effect of Moclobemide. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of tramadol and moclobemide.</p> \n<p><b>Discussion</b> The product monograph for moclobemide states that concomitant use with tramadol is contraindicated.<sup>1</sup> Although not explicitly stated, this warning is likely due to the increased risk for serotonin syndrome. No reports have been published that describe an interaction specifically between these two agents, but numerous case reports describe patients who developed serotonin syndrome while taking tramadol with other serotonin modulators.<sup>2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20</sup><br><br>Tramadol is a weak serotonin reuptake inhibitor and moclobemide is a monoamine oxidase inhibitor capable of preventing the breakdown of serotonin. The mechanism of these interactions is likely related to additive effects on serotonin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Moclobemide [product monograph]. Toronto, Ontario, Canada: Apotex Inc; August 2015. </p>\n<p>2. Egberts AC, ter Borgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. <i>Int Clin Psychopharmacol</i>. 1997;12(3):181-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9248876\">[PubMed 9248876]</a></p>\n<p>3. Lantz MS, Buchalter EN, Giambanco V. Serotonin syndrome following the administration of tramadol with paroxetine. <i>Int J Geriatr Psychiatry</i>. 1998;13(5):343-345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9658268\">[PubMed 9658268]</a></p>\n<p>4. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. <i>Ann Pharmacother</i>. 1997;31(2):175-177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9034418\">[PubMed 9034418]</a></p>\n<p>5. Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. <i>J Clin Psychopharmacol</i>. 2015;35(4):382-388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26082973\">[PubMed 26082973]</a></p>\n<p>6. Shakoor M, Ayub S, Ahad A, Ayub Z. Transient serotonin syndrome cause by concurrent use of tramadol and selective serotonin reuptake inhibitor. <i>Am J Case Rep</i>. 2014;15:562-564. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25540831\">[PubMed 25540831]</a></p>\n<p>7. Falls BA, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2014;55(3):305-309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>8. El-Okdi NS, Lumbrezer D, Karanovic D, Ghose A, Assaly R. Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. <i>Am J Ther</i>. 2014;21(4):e97-e99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24158007\">[PubMed 24158007]</a></p>\n<p>9. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):e52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>10. Lamberg JJ, Gordin VN. Serotonin syndrome in a patient with chronic pain polypharmacy. <i>Pain Med</i>. 2014;15(8):1429-1431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22925399\">[PubMed 22925399]</a></p>\n<p>11. Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. <i>Age Ageing</i>. 2011;40(4):528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21414947\">[PubMed 21414947]</a></p>\n<p>12. John AP, Koloth R. Severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine. <i>Aust N Z J Psychiatry</i>. 2007;41(2):192-193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17484083\">[PubMed 17484083]</a></p>\n<p>13. Kitson R, Carr B. Tramadol and severe serotonin syndrome. <i>Anaesthesia</i>. 2005;60(9):934-935. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16115263\">[PubMed 16115263]</a></p>\n<p>14. Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration. <i>Clin Neuropharmacol</i>. 2004;27(3):150-151. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15190240\">[PubMed 15190240]</a></p>\n<p>15. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. <i>Am J Psychiatry</i>. 2004;161(6):1129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15169709\">[PubMed 15169709]</a></p>\n<p>16. Venlafaxine and tramadol: serotonin syndrome. <i>Prescrire Int</i>. 2004;13(70):57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15148976\">[PubMed 15148976]</a></p>\n<p>17. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. <i>Ann Pharmacother</i>. 2004;38(3):411-413. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14970364\">[PubMed 14970364]</a></p>\n<p>18. Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K. Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. <i>J Clin Psychopharmacol</i>. 2002;22(4):440-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12172351\">[PubMed 12172351]</a></p>\n<p>19. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. <i>J R Soc Med</i>. 1999;92(9):474-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10645303\">[PubMed 10645303]</a></p>\n<p>20. Vizcaychipi MP, Walker S, Palazzo M. Serotonin syndrome triggered by tramadol. <i>Br J Anaesth</i>. 2007;99(6):919. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18006535\">[PubMed 18006535]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10259":"<p><b>Title</b> FluvoxaMINE / Methadone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methadone may enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased methadone effects/toxicities if combined with fluvoxamine. Also monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, mental status changes, autonomic instability, neuromuscular hyperactivity) if these agents are combined.</p> \n<p><b>Discussion</b> Two studies report a significant increase in the methadone concentration to dose ratio after the addition of fluvoxamine to methadone treated patients.<sup>1,2</sup> A case report describes a 28-year-old female stable on methadone therapy who experienced hypoxemia and hypercapnia thought to be due to methadone intoxication 3 weeks after the initiation of fluvoxamine.<sup>3</sup> Lastly, one report describes 38-year-old woman who required increasing doses of methadone (up to 100 mg twice daily) but was unable to maintain therapeutic concentrations or relief of opiate withdrawal symptoms.<sup>4</sup> After fluvoxamine was initiated (in an attempt to take advantage of this pharmacokinetic interaction to increase her methadone concentrations) her symptoms of opiate withdrawal improved. Due to symptoms of over sedation and elevated methadone concentrations, her methadone dose was reduced (to 110 mg once daily) and she was maintained on the combination of fluvoxamine and methadone.<sup>4</sup><br><br>The US Food and Drug Administration (FDA) issued a drug safety communication warning that opioid analgesics may interact with serotonergic medications and lead to the development of serotonin syndrome.<sup>5</sup> Cases of serotonin syndrome in the FDA Adverse Event Reporting System (FAERS) database were reported most frequently with fentanyl and methadone.<sup>5</sup> A new statement will be added to methadone labeling describing these risks.<sup>1</sup> In addition to cases of serotonin syndrome reported in the FAERS database, cases have been published that implicate methadone as a contributing factor in the development of serotonin syndrome when combined with other serotonin modulators.<sup>6,7,8,9</sup><br><br>The mechanism by which fluvoxamine may increase methadone concentrations is likely due to fluvoxamine inhibition of methadone metabolism (via CYP1A2, CYP2C19, and/or CYP3A4). Methadone is thought to be a weak serotonin reuptake inhibitor, so when combined with other serotonin modulators (ie, fluvoxamine), there may be additive effects on serotonin.<sup>9,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. <i>J Clin Psychopharmacol</i>. 1997;17(2):113-117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10950475\">[PubMed 10950475]</a></p>\n<p>2. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. <i>Ther Drug Monit</i>. 1994;16(1):42-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8160253\">[PubMed 8160253]</a></p>\n<p>3. Alderman CP, Frith PA. Fluvoxamine-methadone interaction. <i>Aust N Z J Psychiatry</i>. 1999;33(1):99-101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10197892\">[PubMed 10197892]</a></p>\n<p>4. DeMaria PA Jr, Serota RD. A therapeutic use of the methadone fluvoxamine drug interaction. <i>J Addict Dis</i>. 1999;18(4):5-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10631960\">[PubMed 10631960]</a></p>\n<p>5. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery. Accessed March 24, 2016.</p>\n<p>6. Methadose (methadone) [product monograph]. Saint Laurent, Quebec, Canada: Mallinckrodt Canada ULC; February 2016.</p>\n<p>7. Lee J, Franz L, Goforth HW. Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. <i>Psychosomatics</i>. 2009;50(6):638-639. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19996237\">[PubMed 19996237]</a></p>\n<p>8. Martinez TT, Martinez DN. A case of serotonin syndrome associated with methadone overdose. <i>Proc West Pharmacol Soc</i>. 2008;51:42-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19544673\">[PubMed 19544673]</a></p>\n<p>9. Bush E, Miller C, Friedman I. A case of serotonin syndrome and mutism associated with methadone. <i>J Palliat Med</i>. 2006;9(6):1257-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17187532\">[PubMed 17187532]</a></p>\n<p>10. Hillman AD, Witenko CJ, Sultan SM, Gala G. Serotonin syndrome caused by fentanyl and methadone in a burn injury. <i>Pharmacotherapy</i>. 2015;35(1):112-117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25615513\">[PubMed 25615513]</a></p>\n<p>7. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>Br J Anaesth</i>. 2005;95(4):434-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16051647\">[PubMed 16051647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10260":"<p><b>Title</b> Serotonin Modulators / Anti-Parkinson Agents (Monoamine Oxidase Inhibitor)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Transdermal selegiline product labeling states that use with any serotonin modulator is contraindicated. Labeling for other selegiline products, rasagiline, and safinamide state that their use with certain serotonin modulators is contraindicated (meperidine, tramadol, methadone, St. John’s wort, cyclobenzaprine, dextromethorphan, and any other monoamine oxidase inhibitor) while caution is advised when combined with others.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Anti-Parkinson Agents (Monoamine Oxidase Inhibitor) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoidance of this combination, but monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, mental status changes, autonomic instability, neuromuscular hyperactivity) if selegiline, rasagiline, or safinamide is combined with a serotonin modulator.<br><br>Transdermal selegiline product labeling states that use with any serotonin modulator is contraindicated. <br><br>Labeling for other selegiline products, rasagiline, and safinamide state that their use with certain serotonin modulators is contraindicated (meperidine, tramadol, methadone, St. John’s wort, cyclobenzaprine, dextromethorphan, and any other monoamine oxidase inhibitor) while caution is advised when combined with others.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Monoamine Oxidase Inhibitor) Interacting Members</b> Rasagiline, Safinamide, Selegiline</p>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, Tedizolid, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> Several case reports describe patients who developed possible serotonin syndrome/serotonin toxicity with the use of selegiline or rasagiline.<sup>1,2,3,4,5,6,7,8</sup> Most cases developed when these agents were combined with other serotonin modulators,<sup>1,2,3,4,5,6,7</sup> but 1 case reports that high-dose rasagiline alone may have been responsible for precipitating serotonin syndrome.<sup>8</sup> Other reports describe an interaction between selegiline and fluoxetine where patients developed hypertension and/or ataxia, but a diagnosis of serotonin syndrome/serotonin toxicity was not made.<sup>9,10,11</sup><br><br>Several retrospective analyses have attempted to describe the incidence of serotonin syndrome/serotonin toxicity when selegiline or rasagiline was combined with serotonin modulators.<sup>12,13,14,15,16,17</sup> In one analysis of 28 patients taking selegiline and antidepressants, symptoms consistent with the serotonin syndrome were observed in 1 patient taking fluoxetine.<sup>12</sup> In another report, a survey of study investigators estimated that 4,568 patients had been treated with selegiline and an antidepressant.<sup>13</sup> Eleven patients (0.24%) were reported to have experienced symptoms possibly consistent with the serotonin syndrome, and 2 patients (0.04%) experienced symptoms considered to be serious.<sup>13</sup> In other analyses of the 23 patients who received selegiline and fluoxetine,<sup>14</sup> the 25 patients who received selegiline and antidepressants,<sup>15</sup> the 93 patients who received rasagiline and antidepressants,<sup>16</sup> and the 471 patients treated with rasagiline and antidepressants,<sup>17</sup> no cases of serotonin syndrome/serotonin toxicity were reported. Several small studies of short duration in healthy volunteers also found no evidence of serotonin syndrome/serotonin toxicity when rasagiline or selegiline was combined with serotonin modulators. <sup>18,19,20</sup> Although the risk of serotonin syndrome appears low to negligible in many of these analyses, due to the low incidence of this condition and the relatively small sample sizes in each study, it is difficult to prove an absence of risk. <br><br>Product labeling for selegiline, rasagiline, and safinamide states that serotonin syndrome has been reported when these drugs were combined with other serotonergic drugs.<sup>21,22,23,24</sup> Transdermal selegiline labeling states that use with any serotonergic drug is contraindicated.<sup>21</sup> Product labeling for other selegiline products, rasagiline, and safinamide states that their use with certain serotonin modulators is contraindicated (meperidine, tramadol, methadone, St. John’s wort, cyclobenzaprine, dextromethorphan, and any other monoamine oxidase inhibitor) while caution is advised when combined with others.<sup>22,23,24</sup><br><br>The mechanism of this interaction is due to additive effects on serotonin. Since selegiline, rasagiline and safinamide are monoamine oxidase inhibitors, their use with other agents that increase or prevent the breakdown of serotonin may increase the risk of serotonin syndrome/serotonin toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Duval F, Flabeau O, Razafimahefa J, Spampinato U, Tison F. Encephalopathy associated with rasagiline and sertraline in Parkinson disease: possible serotonin syndrome. <i>Mov Disord</i>. 2013;28(10):1464. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23495033\">[PubMed 23495033]</a></p>\n<p>2. Wu ML, Deng JF. Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline. <i>J Chin Med Assoc</i>. 2009;72(8):446-449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19687003\">[PubMed 19687003]</a></p>\n<p>3. Hinds NP, Hillier CE, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. <i>J Neurol</i>. 2000;247(10):811. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11127542\">[PubMed 11127542]</a></p>\n<p>4. Gitlin MJ. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. <i>J Clin Psychopharmacol</i>. 1997;17(1):66-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9004070\">[PubMed 9004070]</a></p>\n<p>5. Suchowsersky O, deVries JD. Interaction of fluoxetine and selegiline. <i>Can J Psychiatry</i>. 1990;35(6):571-572. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2119876\">[PubMed 2119876]</a></p>\n<p>6. Zomberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. <i>Lancet</i>. 1991;337(8735):246. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1670882\">[PubMed 1670882]</a></p>\n<p>7. Garcia-Monco JC, Padierna A, Gomez Beldarrain M. Selegiline, fluoxetine, and depression in Parkinson's disease. <i>Mov Disord</i>. 1995;10(3):352. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7651457\">[PubMed 7651457]</a></p>\n<p>8. Fernandes C, Reddy P, Kessel B. Rasagiline-induced serotonin syndrome. <i>Mov Disord</i>. 2011;26(4):766-777. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21370275\">[PubMed 21370275]</a></p>\n<p>9. Lefebvre H, Noblet C, Moore N, Wolf LM. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. <i>Clin Endocrinol (Oxf)</i>. 1995;42(1):95-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7889639\">[PubMed 7889639]</a></p>\n<p>10. Montastruc JL, Chamontin B, Senard JM, et al. Pseudophaeochromocytoma in a parkinsonian patient treated with fluoxetine plus selegiline. <i>Lancet</i>. 1993;341(8844):555. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8094789\">[PubMed 8094789]</a></p>\n<p>11. Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction. <i>Ann Pharmacother</i>. 1992;26(10):1300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1421659\">[PubMed 1421659]</a></p>\n<p>12. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. <i>Ann Clin Psychiatry</i>. 1997;9(1):7-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9167831\">[PubMed 9167831]</a></p>\n<p>13. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. <i>Neurology</i>. 1997;48(4):1070-1077. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9109902\">[PubMed 9109902]</a></p>\n<p>14. Waters CH. Fluoxetine and selegiline - lack of significant interaction. <i>Can J Neurol Sci</i>. 1994;21(3):259-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8000982\">[PubMed 8000982]</a></p>\n<p>15. Toyama SC, Iacono RP. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? <i>Ann Pharmacother</i>1994;28(3):405-406. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8193438\">[PubMed 8193438]</a></p>\n<p>16. Smith KM, Eyal E, Weintraub D; ADAGIO Investigators. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. <i>JAMA Neurol</i>. 2015;72(1):88-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25420207\">[PubMed 25420207]</a></p>\n<p>17. Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J; STACCATO study investigators. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). <i>Pharmacotherapy</i>. 2015;34(12):1250-1258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25314256\">[PubMed 25314256]</a></p>\n<p>18. Hilli J, Korhonen T, Laine K. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2009;33(8):1526-1532. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19733607\">[PubMed 19733607]</a></p>\n<p>19. Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. <i>Clin Neuropharmacol</i>. 1997;20(5):419-433. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9331518\">[PubMed 9331518]</a></p>\n<p>20. Dingemanse J, Kneer J, Wallnofer A, et al. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. <i>Clin Neuropharmacol</i>. 1996;19(5):399-414. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8889283\">[PubMed 8889283]</a></p>\n<p>21. Emsam (selegiline) transdermal [prescribing information]. Morgantown, WV: Somerset Pharmaceuticals Inc; March 2015.</p>\n<p>22. Zelapar (selegiline) orally disintegrating tablet [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; July 2014.</p>\n<p>23. Azilect (rasagiline) [prescribing information]. North Wales, PA: TEVA Pharmaceuticals USA Inc; May 2014.</p>\n<p>24. Xadago (safinamide) [prescribing information]. Louisville, KY: US WorldMeds, LLC; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10261":"<p><b>Title</b> OXcarbazepine / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor oxcarbazepine response closely in patients receiving rifampin. Monitor patients receiving this combination for decreases in exposure to the oxcarbazepine 10-monohydroxy metabolite when possible.</p> \n<p><b>Discussion</b> A published case report describes a 33 year old woman receiving long-term treatment with oxcarbazepine (1,200 mg/day) whose predose serum concentration of 10-monohydroxy oxcarbazepine (MHD) decreased by 49% after 7 days of coadministration with rifampin (600 mg/day) and clindamycin (300 mg twice daily).<sup>1</sup> The oxcarbazepine dose was increased to 2,100 mg/day over approximately 3 months of coadministration to reestablish MHD concentrations in the desired therapeutic range. The oxcarbazepine dose was decreased to 1,800 mg/day and then to the pretreatment dose of 1,200 mg/day in the week following rifampin discontinuation, which was sufficient to achieve target MHD serum concentrations at that time.<br><br>The mechanism of the possible interaction between rifampin and oxcarbazepine has not been established. Rifampin may induce MHD metabolism, which occurs primarily via glucuronidation. Oxcarbazepine product labeling does not describe any potential for an interaction with rifampin, but does offer recommendations for monitoring and dose adjustment when used in combination with other enzyme-inducing medications such as carbamazepine, phenytoin, and phenobarbital.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sigaroudi A, Kullak-Ublick GA, Weiler S. Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine. <i>Eur J Clin Pharmacol</i>. 2016;72(3):377-378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26631062\">[PubMed 26631062]</a></p>\n<p>2. Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10262":"<p><b>Title</b> GuanFACINE / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Reduce the guanfacine dose by 50% when initiating concomitant therapy with a moderate CYP3A4 inhibitor. When discontinuing moderate CYP3A4 inhibitor treatment, increase the guanfacine dose to the recommended dose range. Monitor patients receiving guanfacine with a moderate CYP3A4 inhibitor for evidence of excessive guanfacine response (eg, hypotension, bradycardia, CNS depression, etc.).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in guanfacine US product labeling, coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 6 days) increased the maximum concentration and AUC of guanfacine (4 mg single oral dose) by 1.7- and 3.1-fold, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A-mediated guanfacine metabolism. No data are available characterizing the impact of moderate CYP3A4 inhibitors on guanfacine exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Intuniv (guanfacine) [prescribing information]. Wayne, PA: Shire US Inc; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10263":"<p><b>Title</b> Fosamprenavir / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may increase the serum concentration of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of ritonavir-boosted fosamprenavir together with ombitasvir/paritaprevir/ritonavir/dasabuvir is not recommended. Consider using a reduced dose of fosamprenavir 1400 mg once daily (unboosted) when coadministered with ombitasvir/paritaprevir/ritonavir/dasabuvir. Monitor response to the combination closely.</p> \n<p><b>Discussion</b> Specific information regarding this presumed interaction are not available, but the prescribing information for both fosamprenavir and the Canadian brand of ombitasvir/paritaprevir/ritonavir/dasabuvir (Holkira Pak) caution that concurrent use of ritonavir-boosted fosamprenavir with ombitasvir/paritaprevir/ritonavir/dasabuvir is not recommended.<sup>1,2</sup> If fosamprenavir (unboosted) must be used together with ombitasvir/paritaprevir/ritonavir/dasabuvir, consider using a reduced dose of fosamprenavir 1400 mg once daily.<sup>1</sup><br><br>Fosamprenavir, paritaprevir, and ritonavir are each CYP3A substrates, and amprenavir (active metabolite of fosamprenavir) and ritonavir are both inhibitors of CYP3A. As a result, use of this combination could result in impaired metabolism and increased serum concentrations of amprenavir, paritaprevir, and/or ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lexiva (fosamprenavir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; March 2016.</p>\n<p>2. Holkira Pak (ombitasvir, paritaprevir, ritonavir, and dasabuvir) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10264":"<p><b>Title</b> CYP2D6 Substrates (High risk with Inhibitors) / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Asunaprevir may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of asunaprevir is contraindicated in combination with drugs that are highly-dependent on CYP2D6 for their metabolism and for which increased concentrations are associated with serious ventricular arrhythmias and sudden death. Specific examples cited in the product monograph include thioridazine, flecainide, and propafenone. Use caution with concurrent use of any CYP2D6 substrate and monitor patient response to those drugs closely.</p>\n<div>\n <p><b>CYP2D6 Substrates (High risk with Inhibitors) Interacting Members</b> Ajmaline, Amitriptyline, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, AtoMOXetine, Brexpiprazole, Captopril, Carvedilol, Chloroquine, Chlorpheniramine, ChlorproMAZINE, ClomiPRAMINE, Codeine, Dapoxetine, Desipramine, Deutetrabenazine, Dextromethorphan, Doxepin (Systemic), Doxepin (Topical), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eliglustat, Flecainide, FLUoxetine, FluPHENAZine, FluvoxaMINE, Gefitinib, Haloperidol, Iloperidone, Imipramine, Indoramin, Maprotiline, Mequitazine, Methamphetamine, Metoprolol, Mexiletine, Mirtazapine, Nefazodone, Nortriptyline, Olmutinib, PARoxetine, Perhexiline, Perphenazine, Pimozide, Primaquine, Procainamide, Propafenone, Propranolol, Protriptyline, RisperiDONE, Syrian Rue, Tamoxifen, Tetrabenazine, Thioridazine, Timolol (Ophthalmic), Timolol (Systemic), Tolterodine, Trimipramine, Tropisetron, Venlafaxine, Vortioxetine, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The AUC of the CYP2D6 substrate dextromethorphan was an average of 3.9-fold higher with concurrent use of asunaprevir in a study where subjects received a single dose of dextromethorphan (30 mg) together with asunaprevir 200 mg twice/day (n=17).<sup>1</sup><br><br>According to the Canadian product monograph, asunaprevir is contraindicated in combination with drugs that are highly-dependent on CYP2D6 for their metabolism and for which increased concentrations are associated with serious ventricular arrhythmias and sudden death. Specific examples cited in the product monograph include thioridazine, flecainide, and propafenone. Other CYP2D6 substrates, such as the tricyclic antidepressants, should be used with caution and close monitoring; dose adjustments may be necessary. <br><br>Asunaprevir is a moderate inhibitor of CYP2D6 and will likely reduce the metabolism of CYP2D6 substrates, resulting in reduced substrate clearance and increased serum concentrations. Increased effects and toxicities of the substrates would be expected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10265":"<p><b>Title</b> Thioridazine / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Asunaprevir may increase the serum concentration of Thioridazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of asunaprevir is contraindicated in combination with thioridazine and with other drugs that are highly-dependent on CYP2D6 for their metabolism and for which increased concentrations are associated with serious ventricular arrhythmias and sudden death. Specific examples cited in the product monograph include thioridazine, flecainide, and propafenone.</p> \n<p><b>Discussion</b> The AUC of the CYP2D6 substrate dextromethorphan was an average of 3.9-fold higher with concurrent use of asunaprevir in a study where subjects received a single dose of dextromethorphan (30 mg) together with asunaprevir 200 mg twice/day (n=17).<sup>1</sup><br><br>According to the Canadian product monograph, asunaprevir is contraindicated in combination with drugs that are highly-dependent on CYP2D6 for their metabolism and for which increased concentrations are associated with serious ventricular arrhythmias and sudden death. Specific examples cited in the product monograph include thioridazine, flecainide, and propafenone. Other CYP2D6 substrates, such as the tricyclic antidepressants, should be used with caution and close monitoring; dose adjustments may be necessary. <br><br>Asunaprevir is a moderate inhibitor of CYP2D6 and will likely reduce the metabolism of CYP2D6 substrates, resulting in reduced substrate clearance and increased serum concentrations. Increased effects and toxicities of the substrates would be expected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10266":"<p><b>Title</b> Flecainide / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Asunaprevir may increase the serum concentration of Flecainide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of asunaprevir is contraindicated in combination with flecainide and with other drugs that are highly-dependent on CYP2D6 for their metabolism and for which increased concentrations are associated with serious ventricular arrhythmias and sudden death. Specific examples cited in the product monograph include thioridazine, flecainide, and propafenone.</p> \n<p><b>Discussion</b> The AUC of the CYP2D6 substrate dextromethorphan was an average of 3.9-fold higher with concurrent use of asunaprevir in a study where subjects received a single dose of dextromethorphan (30 mg) together with asunaprevir 200 mg twice/day (n=17).<sup>1</sup><br><br>According to the Canadian product monograph, asunaprevir is contraindicated in combination with drugs that are highly-dependent on CYP2D6 for their metabolism and for which increased concentrations are associated with serious ventricular arrhythmias and sudden death. Specific examples cited in the product monograph include thioridazine, flecainide, and propafenone. Other CYP2D6 substrates, such as the tricyclic antidepressants, should be used with caution and close monitoring; dose adjustments may be necessary. <br><br>Asunaprevir is a moderate inhibitor of CYP2D6 and will likely reduce the metabolism of CYP2D6 substrates, resulting in reduced substrate clearance and increased serum concentrations. Increased effects and toxicities of the substrates would be expected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10267":"<p><b>Title</b> Propafenone / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Asunaprevir may increase the serum concentration of Propafenone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of asunaprevir is contraindicated in combination with propafenone and with other drugs that are highly-dependent on CYP2D6 for their metabolism and for which increased concentrations are associated with serious ventricular arrhythmias and sudden death. Specific examples cited in the product monograph include thioridazine, flecainide, and propafenone.</p> \n<p><b>Discussion</b> The AUC of the CYP2D6 substrate dextromethorphan was an average of 3.9-fold higher with concurrent use of asunaprevir in a study where subjects received a single dose of dextromethorphan (30 mg) together with asunaprevir 200 mg twice/day (n=17).<sup>1</sup><br><br>According to the Canadian product monograph, asunaprevir is contraindicated in combination with drugs that are highly-dependent on CYP2D6 for their metabolism and for which increased concentrations are associated with serious ventricular arrhythmias and sudden death. Specific examples cited in the product monograph include thioridazine, flecainide, and propafenone. Other CYP2D6 substrates, such as the tricyclic antidepressants, should be used with caution and close monitoring; dose adjustments may be necessary. <br><br>Asunaprevir is a moderate inhibitor of CYP2D6 and will likely reduce the metabolism of CYP2D6 substrates, resulting in reduced substrate clearance and increased serum concentrations. Increased effects and toxicities of the substrates would be expected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10268":"<p><b>Title</b> Asunaprevir / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of asunaprevir with any moderate CYP3A4 inhibitor is contraindicated per the asunaprevir product monograph.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> While specific data regarding the potential interaction between asunaprevir and moderate CYP3A4 inhibitors are not available, concomitant use is contraindicated per the asunaprevir product monograph due to the potential for increases in asunaprevir exposure.<sup>1</sup><br><br>The asunaprevir AUC was an average of 9.65-fold higher with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study where subjects received ketoconazole (200 mg twice daily for 15 days) with asunaprevir (200 mg daily).<sup>1</sup> The suspected primary mechanism of this interaction is ketoconazole inhibition of the CYP3A4-mediated asunaprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10269":"<p><b>Title</b> Asunaprevir / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Asunaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of asunaprevir with any strong CYP3A4 inhibitor is contraindicated per the asunaprevir product monograph.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The asunaprevir AUC was an average of 9.65-fold higher with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study where subjects received ketoconazole (200 mg twice daily for 15 days) with asunaprevir (200 mg daily).<sup>1</sup> The suspected primary mechanism of this interaction is ketoconazole inhibition of the CYP3A4-mediated asunaprevir metabolism.<br><br>Concomitant use of asunaprevir with any strong CYP3A4 inhibitor is contraindicated per the asunaprevir product monograph due to the potential for increases in asunaprevir exposure.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10270":"<p><b>Title</b> Asunaprevir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Asunaprevir. This effect is most likely with longer-term coadministration; single-dose rifampin may increase asunaprevir concentrations. RifAMPin may increase the serum concentration of Asunaprevir. This effect is likely following only single-dose or short-term rifampin administration. Longer-term coadministration is likely to result in decreased asunaprevir concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of asunaprevir in combination with rifampin is contraindicated per the asunaprevir Canadian product monograph.</p> \n<p><b>Discussion</b> Coadministration of single-dose rifampin (600 mg) increased single-dose asunaprevir (200 mg) AUC by 14.8-fold, in a study of 20 healthy volunteers as summarized in the asunaprevir product monograph.<sup>1</sup> In contrast, the asunaprevir AUC was an average of 21% lower after coadministration of multi-dose rifampin (600 mg daily) with asunaprevir (600 mg twice daily).<sup>1</sup><br><br>These apparently disparate findings are likely the result of both rifampin inhibition of OATP transporters and induction of CYP3A4. Specifically, OATP 1B1 and 2B1 transporters are involved in the hepatic uptake of asunaprevir, so rifampin inhibition of this process would be expected to result in increased serum concentrations of asunaprevir but decreased therapeutic effects due to limited liver distribution. However, even with rifamin’s inhibitory effects on OATP transporters, use of rifampin for longer than a few days would be expected to result in increased CYP3A4-mediated metabolism of asunaprevir via rifampin induction of CYP3A4. Based on the available data, it appears that the CYP3A4 inducing effect overcomes the OATP inhibition with longer-term concomitant use of rifampin and asunaprevir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10271":"<p><b>Title</b> Asunaprevir / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of asunaprevir in combination with any strong or moderate CYP3A4 inducer is contraindicated per the asunaprevir Canadian product monograph.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Although there are no specific data concerning the combined use of a moderate CYP3A4 inducer with asunaprevir, the use of asunaprevir in combination with any strong or moderate CYP3A4 inducer is contraindicated per the asunaprevir Canadian product monograph.<sup>1</sup><br><br>The asunaprevir AUC was an average of 21% lower after coadministration of the strong CYP3A4 inducer rifampin in a study where subjects received multi-dose rifampin (600 mg daily) with asunaprevir (600 mg twice daily).<sup>1</sup> Of note, rifampin is also an inhibitor of the hepatic uptake transporter OATP1B1, which may diminish the impact of rifampin's CYP3A4 induction. Coadministration of single-dose rifampin (600 mg) increased single-dose asunaprevir (200 mg) AUC by 14.8-fold, in a study of 20 healthy volunteers as summarized in the asunaprevir product monograph.<sup>1</sup> However, even with rifamin’s inhibitory effects on OATP transporters, use of rifampin for longer than a few days would be expected to result in increased CYP3A4-mediated metabolism of asunaprevir via rifampin induction of CYP3A4. Based on the available data, it appears that the CYP3A4 inducing effect overcomes the OATP inhibition with longer-term concomitant use of rifampin and asunaprevir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10272":"<p><b>Title</b> Asunaprevir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Asunaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of asunaprevir in combination with any strong or moderate CYP3A4 inducer is contraindicated per the asunaprevir Canadian product monograph.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Although there are no specific data concerning the combined use of a moderate CYP3A4 inducer with asunaprevir, the use of asunaprevir in combination with any strong or moderate CYP3A4 inducer is contraindicated per the asunaprevir Canadian product monograph.<sup>1</sup><br><br>The asunaprevir AUC was an average of 21% lower after coadministration of the strong CYP3A4 inducer rifampin in a study where subjects received multi-dose rifampin (600 mg daily) with asunaprevir (600 mg twice daily).<sup>1</sup> Of note, rifampin is also an inhibitor of the hepatic uptake transporter OATP1B1, which may diminish the impact of rifampin's CYP3A4 induction. Coadministration of single-dose rifampin (600 mg) increased single-dose asunaprevir (200 mg) AUC by 14.8-fold, in a study of 20 healthy volunteers as summarized in the asunaprevir product monograph.<sup>1</sup> However, even with rifamin’s inhibitory effects on OATP transporters, use of rifampin for longer than a few days would be expected to result in increased CYP3A4-mediated metabolism of asunaprevir via rifampin induction of CYP3A4. Based on the available data, it appears that the CYP3A4 inducing effect overcomes the OATP inhibition with longer-term concomitant use of rifampin and asunaprevir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10273":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of other Monoamine Oxidase Inhibitors. Monoamine Oxidase Inhibitors may enhance the serotonergic effect of other Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of 2 or more monoamine oxidase inhibitors (MAOIs). Many MAOI product labels state that use with (or within 14 days of) other MAOIs is contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Prescribing information for most monoamine oxidase inhibitors (MAOIs) states that use with (or within 14 days of) other MAOIs is contraindicated.<sup>1,2,3,4,5,6,7,8</sup> The combination of 2 MAOIs may increase the risk for serotonin syndrome and/or hypertensive crisis.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zyvox (linezolid) [prescribing information]. New York, NY: Pfizer Inc; June 2015.</p>\n<p>2. Emsam (selegiline) transdermal [prescribing information]. Morgantown, WV: Somerset Pharmaceuticals Inc; March 2015.</p>\n<p>3. Marplan (isocarboxazid) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals Inc; June 2007.</p>\n<p>4. Nardil (phenelzine) [prescribing information]. New York, NY: Pfizer Inc; May 2007.</p>\n<p>5. Azilect (rasagiline) [prescribing information]. North Wales, PA: TEVA Pharmaceuticals USA Inc; May 2014.</p>\n<p>6. Parnate (tranylcypromine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; May 2010.</p>\n<p>7. Manerix (moclobemide) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; November 2014.</p>\n<p>8. Xadago (safinamide) [prescribing information]. Louisville, KY: US WorldMeds, LLC; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10274":"<p><b>Title</b> Serotonin Modulators / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Linezolid may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators at least 2 weeks (or longer for agents with longer half-lives such as fluoxetine or vortioxetine) prior to the administration of linezolid. If more urgent initiation of linezolid is needed, the availability of alternative agents and interventions should be considered. If the benefit of linezolid under such circumstances outweighs the risk of serotonin toxicity, discontinue the serotonin modulator immediately and monitor closely for signs of serotoin syndrome/serotonin toxicity for 2 weeks (3 weeks for vortioxetine, 5 weeks for fluoxetine) after the last serotonin modulator dose, or 24 hours after the last dose of linezolid, whichever comes first. Serotonin modulator treatment may be resumed 24 hours after the last dose of linezolid.</p>\n<div>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, Tedizolid, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin syndrome/serotonin toxicity developing in patients receiving linezolid during or shortly after treatment with serotonin modulators, including selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, paroxetine, sertraline),<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> tricyclic antidepressants (amitriptyline, imipramine),<sup>12,18</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>7,18,19,20,21,22</sup> mirtazapine,<sup>9,12</sup> and trazodone.<sup>12,13</sup> Additional agents with serotonergic properties, including tramadol, metoclopramide, risperidone, bupropion, lithium, methadone, and fentanyl, were co-prescribed in some of these cases.<sup>12,13,14,20</sup><br><br>According to linezolid prescribing information, symptoms of serotonin syndrome/serotonin toxicity were not described in initial clinical studies with linezolid, nor were such symptoms seen in a clinical study where dextromethorphan (a serotonin reuptake inhibitor) was coadministered with linezolid to healthy volunteers.<sup>23,24</sup> However, because linezolid is a reversible, nonselective inhibitor of monoamine oxidase, its combination with other serotonergic agents could theoretically contribute to development of serotonin syndrome/serotonin toxicity.<sup>23</sup> Given the large number of postmarketing reports that appear to demonstrate such effects clinically, coadministration of linezolid with serotonergic agents should be undertaken with caution, and patients receiving such therapy should be closely monitored.<sup>23</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lavery S, Ravi H, McDaniel WW, et al. Linezolid and serotonin syndrome. <i>Psychosomatics</i>. 2001;42(5):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11739912\">[PubMed 11739912]</a></p>\n<p>2. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. <i>Clin Infect Dis</i>. 2002;34(12):1651-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032904\">[PubMed 12032904]</a></p>\n<p>3. Bernard L, Stern R, Lew D, et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. <i>Clin Infect Dis</i>. 2003;36(9):1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12715317\">[PubMed 12715317]</a></p>\n<p>4. Hachem RY, Hicks K, Huen A, et al. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. <i>Clin Infect Dis</i>. 2003;37(1):e8-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12830431\">[PubMed 12830431]</a></p>\n<p>5. Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram. <i>J Am Med Dir Assoc</i>. 2004;5(2):111-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984623\">[PubMed 14984623]</a></p>\n<p>6. Thomas CR, Rosenberg M, Blythe V, et al. Serotonin syndrome and linezolid. <i>J Am Acad Child Adolesc Psychiatry</i>. 2004;43(7):790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15213578\">[PubMed 15213578]</a></p>\n<p>7. Bergeron L, Boule M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. <i>Ann Pharmacother</i>. 2005;39(5):956-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15827071\">[PubMed 15827071]</a></p>\n<p>8. Morales N, Vermette H. Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine. <i>Psychosomatics</i>. 2005;46(3):274-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15883150\">[PubMed 15883150]</a></p>\n<p>9. DeBellis RJ, Schaefer OP, Liquori M, et al. Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient. <i>J Intensive Care Med</i>. 2005;20(6):351-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16280409\">[PubMed 16280409]</a></p>\n<p>10. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. <i>Pharmacotherapy</i>. 2006;26(2):269-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>11. Sola CL, Bostwick JM, Hart DA, et al. Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise. <i>Mayo Clin Proc</i>. 2006;81(3):330-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16529136\">[PubMed 16529136]</a></p>\n<p>12. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. <i>Clin Infect Dis</i>. 2006;42(11):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652315\">[PubMed 16652315]</a></p>\n<p>13. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. <i>Clin Infect Dis</i>. 2006;43(2):180-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16779744\">[PubMed 16779744]</a></p>\n<p>14. Steinberg M, Morin AK. Mild serotonin syndrome associated with concurrent linezolid and fluoxetine. <i>Am J Health Syst Pharm</i>. 2007;64(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17189581\">[PubMed 17189581]</a></p>\n<p>15. Lorenz RA, Vandenberg AM, Canepa EA. Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases. <i>Int J Psychiatry Med</i>. 2008;38(1):81-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18624020\">[PubMed 18624020]</a></p>\n<p>16. McClean M, Walsh JC, Condon F. Serotonin syndrome in an orthopaedic patient secondary to linezolid therapy for MRSA infection. <i>Ir J Med Sci</i>. 2011;180(1):285-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20886306\">[PubMed 20886306]</a></p>\n<p>17. Go AC, Golightly LK, Barber GR. Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment. <i>Drug Metabol Drug Interact</i>. 2010;25(1-4):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21417793\">[PubMed 21417793]</a></p>\n<p>18. Miller DG, Lovell EO. Antibiotic-induced serotonin syndrome. <i>J Emerg Med</i>. 2011;40(1):25-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18455905\">[PubMed 18455905]</a></p>\n<p>19. Jones SL, Athan E, O'Brien D. Serotonin syndrome due to co-administration of linezolid and venlafaxine. <i>J Antimicrob Chemother</i>. 2004;54(1):289-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15140859\">[PubMed 15140859]</a></p>\n<p>20. Strouse TB, Kerrihard TN, Forscher CA, et al. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110838\">[PubMed 17110838]</a></p>\n<p>21. Packer S, Berman SA. Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. <i>Am J Psychiatry</i>. 2007;164(2):346-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267801\">[PubMed 17267801]</a></p>\n<p>22. Mason LW, Randhawa KS, Carpenter EC. Serotonin toxicity as a consequence of linezolid use in revision hip arthroplasty. <i>Orthopedics</i>. 2008;31(11):1140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226083\">[PubMed 19226083]</a></p>\n<p>23. Zyvox (linezolid) [prescribing information]. New York, NY: Pharmacia and Upjohn Company; June 2015.</p>\n<p>24. Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. <i>J Clin Pharmacol</i>. 2001;41(5):563-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10275":"<p><b>Title</b> Asunaprevir / OATP1B1/SLCO1B1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Asunaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of asunaprevir in combination with any strong SLCO1B1 (aka OATP1B1) inhibitors is contraindicated per the asunaprevir Canadian product monograph.</p>\n<div>\n <p><b>OATP1B1/SLCO1B1 Inhibitors Interacting Members</b> Cobicistat, CycloSPORINE (Systemic), Daclatasvir, Eltrombopag, Gemfibrozil, Glecaprevir and Pibrentasvir, Letermovir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, RifAMPin, Simeprevir, Teriflunomide, Velpatasvir, Voxilaprevir</p>\n</div> \n<p><b>Discussion</b> The asunaprevir AUC was an average of 14.8-fold higher after coadministration of the strong SLCO1B1 (aka OATP1B1) inhibitor rifampin in a study where subjects (n=20) received single-dose rifampin (600 mg) together with single-dose asunaprevir (200 mg) as summarized in the asunaprevir product monograph.<sup>1</sup><br><br>Inhibition of the SLCO1B1 hepatic uptake of asunaprevir is the likely mechanism for this interaction. Such inhibition would result in less asunaprevir distribution into the liver, both impairing its effectiveness and limiting its access to drug metabolizing enzymes, leading to increased serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10276":"<p><b>Title</b> Digoxin / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Asunaprevir may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased digoxin effects and/or concentrations if asuneprevir is started or if the asunaprevir dose is increased.</p> \n<p><b>Discussion</b> The AUC of digoxin was increased 1.3-fold when a single dose of digoxin (0.5 mg) was administered in combination with asunaprevir 200 mg twice daily in a clinical study of 16 healthy volunteers.<sup>1</sup> The asunaprevir labeling recommends that asunaprevir should be used with caution when administered with P-glycoprotein (Pgp) substrates, such as digoxin, as the presumed mechanism for this interaction is asunaprevir inhibition of Pgp-mediated digoxin transport.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10277":"<p><b>Title</b> Ethinyl Estradiol / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Asunaprevir may decrease the serum concentration of Ethinyl Estradiol. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> For patients using hormone-based contraception, a high-dose oral contraceptive containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone is recommended during treatment with asunaprevir.</p> \n<p><b>Discussion</b> The AUC of ethinyl estradiol was reduced by 14% to 28% when ethinyl estradiol (30 mcg and 35 mcg doses) was combined with asunaprevir (either 600 mg twice daily or 100 mg twice daily with daclatasvir) in studies of 17 and 36 subjects.<sup>1</sup><br><br>The likely mechanism for this observed reduction in ethinyl estradiol concentrations is induction of its CYP3A4 metabolism by asunaprevir, which is a weak CYP3A4 inducer.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10278":"<p><b>Title</b> Norgestimate / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Asunaprevir may decrease serum concentrations of the active metabolite(s) of Norgestimate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> For patients using hormone-based contraception, a high-dose oral contraceptive containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone is recommended during treatment with asunaprevir.</p> \n<p><b>Discussion</b> The AUC of norelgestromin (active metabolite of norgestimate) was reduced by 34% when ethinyl estradiol (35 mcg) and norgestimate (0.180/0.215/ 0.250 mg) once daily were combined with a daily dose of asunaprevir 600 mg twice daily in a study of 17 subjects.<sup>1</sup> Conversely, concentrations of norethindrone were not significantly changed when given with asunaprevir, likely explaining the recommendation that patients using hormone-based contraception should use a high-dose oral contraceptive containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone.<sup>1</sup><br><br>The likely mechanism for this observed reduction in norgestimate/norelgestromin concentrations is induction of its CYP3A4 metabolism by asunaprevir, which is a weak CYP3A4 inducer.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10279":"<p><b>Title</b> Norelgestromin / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Asunaprevir may decrease the serum concentration of Norelgestromin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> For patients using hormone-based contraception, a high-dose oral contraceptive containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone is recommended during treatment with asunaprevir.</p> \n<p><b>Discussion</b> The AUC of norelgestromin (active metabolite of norgestimate) was reduced by 34% when ethinyl estradiol (35 mcg) and norgestimate (0.180/0.215/ 0.250 mg) once daily were combined with a daily dose of asunaprevir 600 mg twice daily in a study of 17 subjects.<sup>1</sup> Conversely, concentrations of norethindrone were not significantly changed when given with asunaprevir, likely explaining the recommendation that patients using hormone-based contraception should use a high-dose oral contraceptive containing at least 30 mcg of ethinyl estradiol combined with norethindrone acetate/norethindrone.<sup>1</sup><br><br>The likely mechanism for this observed reduction in norgestimate/norelgestromin concentrations is induction of its CYP3A4 metabolism by asunaprevir, which is a weak CYP3A4 inducer.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10280":"<p><b>Title</b> Reboxetine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reboxetine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Reboxetine should not be used with a monoamine oxidase inhibitor (MAOI), and this combination is specifically contraindicated in some reboxetine labels. Concomitant use could result in a tyramine-like effect (ie, dangerous increases in blood pressure and possible target organ damage) and/or other possible effects such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> As reboxetine is an effector of brain monoamine concentrations, concomitant use with a monoamine oxidase inhibitor (MAOI) should be avoided.<sup>1,2,3</sup> Though the reboxetine labeling contains little information about the anticipated consequences of this interaction, the labeling for a similar drug (atomoxetine) states that concomitant use of an MAOI and other similar drugs have produced serious, even fatal, events including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Edronax (reboxetine) [summary of product characteristics]. Kent, United Kingdon: Pfizer Limited; October 2015.</p>\n<p>2. Edronax (reboxetine) [summary of product characteristics]. West Ryde, New South Wales, Australia: Pfizer Australia Pty Ltd; October 2012.</p>\n<p>3. Prolift (reboxetine) [summary of product characteristics]. Guarulhos, Sao Paulo, Brazil: Pfizer Ltda; October 2014.</p>\n<p>4. Strattera (atomoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10281":"<p><b>Title</b> Reboxetine / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The recommended management of this interaction varies among international product labels.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Reboxetine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to reboxetine closely, and watch specifically for evidence of adverse effects or toxicity, if reboxetine is used together with a strong inhibitor of CYP3A4. The UK labeling for reboxetine specifically recommends not using reboxetine together with strong CYP3A4 inhibitors since reboxetine has a narrow therapeutic index.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Reboxetine concentrations were approximately 50% higher with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study of healthy volunteers.<sup>1,2,3</sup><br><br>This interaction is likely the result of impaired reboxetine CYP3A4-mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Edronax (reboxetine) [summary of product characteristics]. Kent, United Kingdon: Pfizer Limited; October 2015.</p>\n<p>2. Edronax (reboxetine) [summary of product characteristics]. West Ryde, New South Wales, Australia: Pfizer Australia Pty Ltd; October 2012.</p>\n<p>3. Prolift (reboxetine) [summary of product characteristics]. Guarulhos, Sao Paulo, Brazil: Pfizer Ltda; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10282":"<p><b>Title</b> Ergot Derivatives / Reboxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Reboxetine may enhance the hypertensive effect of Ergot Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The UK and Australian reboxetine labeling state that concurrent use of reboxetine and ergot derivatives may result in increased blood pressure. Patients on concurrent therapy of reboxetine and ergot derivatives should be monitored closely for increases in blood pressure.</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Cabergoline, Dihydroergotamine, Ergoloid Mesylates, Ergonovine, Ergotamine, Methylergonovine, Pergolide<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> The UK and Australian reboxetine labeling state that concurrent use of reboxetine and ergot derivatives may result in an increased blood pressure.<sup>1,2</sup><br><br>A possible mechanism for this interaction is the additive hypertensive effects from the alpha-1 agonist activity of ergotamine and an increase in norepinephrine levels due to reboxetine's inhibition of norepinephrine reuptake. Atomexetine, a drug with a similar mechanism of action to that of reboxetine, has been shown to elevate blood pressure,<sup>3</sup> further supporting the proposed mechanism of interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Edronax (reboxetine) [summary of product characteristics]. Kent, United Kingdon: Pfizer Limited; October 2015.</p>\n<p>2. Edronax (reboxetine) [summary of product characteristics]. West Ryde, New South Wales, Australia: Pfizer Australia Pty Ltd; October 2012.</p>\n<p>3. Strattera (atomoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10283":"<p><b>Title</b> Monoamine Oxidase Inhibitors / FentaNYL</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> FentaNYL may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid fentanyl use in patients who have used monoamine oxidase inhibitors within the past 14 days due to reports of unpredictable but severe adverse effects.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Two case reports describe adverse events in patients who received fentanyl in combination with a monoamine oxidase inhibitor (MAOI).<sup>1,2</sup> Both cases report hypertension associated with the combination, with associated shivering, hyperthermia, and eventual hypotension and death in one case.<sup>1</sup> In addition, the combination of fentanyl and other serotonergic medications (eg, serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, methadone) has been associated with the development of serotonin syndrome/serotonin toxicity in numerous other reports.<sup>3,4,5,6,7,8,9,10,11,12</sup><br><br>Fentanyl prescribing information cautions against concurrent use of fentanyl with an MAOI, recommending that fentanyl be avoided in patients who have used an MAOI within the past 14 days due to reports of unpredictable but severe adverse effects.<sup>13</sup> <br><br>The likely mechanism of this possible interaction appears to be serotonergic toxicity resulting from a combination of the possible and relatively weak serotonin reuptake inhibitor activity of fentanyl and the known serotonin-potentiating effects of the MAOIs.<sup>12,14</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Noble WH, Baker A. MAO inhibitors and coronary artery surgery: a patient death. <i>Can J Anaesth</i>. 1992;39(10):1061-1066. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1464133\">[PubMed 1464133]</a></p>\n<p>2. Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ. Cardiac surgery in a patient taking monoamine oxidase inhibitors: an adverse fentanyl reaction. <i>Anesth Analg</i>. 1994;78(3):593-597. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8109782\">[PubMed 8109782]</a></p>\n<p>3. Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J. Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy. <i>J Clin Anesth</i>. 2015;27(3):247-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25499271\">[PubMed 25499271]</a></p>\n<p>4. Pedavally S, Fugate JE, Rabinstein AA. Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. <i>Neurocrit Care</i>. 2014;21(1):108-113. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24052457\">[PubMed 24052457]</a></p>\n<p>5. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>6. Alkhatib AA, Peterson KA, Tuteja AK. Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy. <i>Dig Dis Sci</i>. 2010;55(1):215-216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19165596\">[PubMed 19165596]</a></p>\n<p>7. Kirschner R, Donovan JW. Serotonin syndrome precipitated by fentanyl during procedural sedation. <i>J Emerg Med</i>. 2010;38(4):477-480. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18757161\">[PubMed 18757161]</a></p>\n<p>8. Rang ST, Field J, Irving C. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. <i>Can J Anaesth</i>. 2008;55(8):521-525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18676387\">[PubMed 18676387]</a></p>\n<p>9. Ozkardesler S, Gurpinar T, Akan M, et al. A possible perianesthetic serotonin syndrome related to intrathecal fentanyl. <i>J Clin Anesth</i>. 2008;20(2):143-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18410872\">[PubMed 18410872]</a></p>\n<p>10. Ailawadhi S, Sung KW, Carlson LA, Baer MR. Serotonin syndrome caused by interaction between citalopram and fentanyl. <i>J Clin Pharm Ther</i>. 2007;32(2):199-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17381671\">[PubMed 17381671]</a></p>\n<p>11. Roy S, Fortier LP. Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafaxine. <i>Can J Anaesth</i>. 2003;50(1):32-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12514147\">[PubMed 12514147]</a></p>\n<p>12. Hillman AD, Witenko CJ, Sultan SM, Gala G. Serotonin syndrome caused by fentanyl and methadone in a burn injury. <i>Pharmacotherapy</i>. 2015;35(1):112-117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25615513\">[PubMed 25615513]</a></p>\n<p>13. Duragesic (fentanyl) transdermal [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; April 2014.</p>\n<p>14. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>Br J Anaesth</i>. 2005;95(4):434-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16051647\">[PubMed 16051647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10284":"<p><b>Title</b> Loop Diuretics / Reboxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Reboxetine may enhance the hypokalemic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs and symptoms of hypokalemia when using a potassium-depleting diuretic together with reboxetine.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the reboxetine UK labeling, potassium levels were reduced by 0.8 mmol/litre (ie, 0.8 mEq/L) after 14 weeks of reboxetine use in elderly patients, though potassium levels remained within normal limits.<sup>1</sup> Though there are no clinical data concerning use with diuretics currently available, the UK and Australian labeling caution about the possibility of hypokalemia with concomitant use of reboxetine and potassium-depleting diuretics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Edronax (reboxetine) [summary of product characteristics]. Kent, United Kingdon: Pfizer Limited; October 2015.</p>\n<p>2. Edronax (reboxetine) [summary of product characteristics]. West Ryde, New South Wales, Australia: Pfizer Australia Pty Ltd; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10285":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Reboxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Reboxetine may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs and symptoms of hypokalemia when using a potassium-depleting diuretic together with reboxetine.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the reboxetine UK labeling, potassium levels were reduced by 0.8 mmol/litre (ie, 0.8 mEq/L) after 14 weeks of reboxetine use in elderly patients, though potassium levels remained within normal limits.<sup>1</sup> Though there are no clinical data concerning use with diuretics currently available, the UK and Australian labeling caution about the possibility of hypokalemia with concomitant use of reboxetine and potassium-depleting diuretics.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Edronax (reboxetine) [summary of product characteristics]. Kent, United Kingdon: Pfizer Limited; October 2015.</p>\n<p>2. Edronax (reboxetine) [summary of product characteristics]. West Ryde, New South Wales, Australia: Pfizer Australia Pty Ltd; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10286":"<p><b>Title</b> Cardiac Glycosides / Minocycline</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to the specific IV formulation of minocycline.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Minocycline may enhance the bradycardic effect of Cardiac Glycosides. Specifically, the magnesium in the IV minocycline product may enhance the bradycardic effect of cardiac glycosides. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> The labeling for IV minocycline cautions that concurrent administration with cardiac glycosides may result in a potentially serious drug interaction.<sup>1</sup> This caution appears related to the relatively high magnesium content in the IV formulation (2.2 mEq per 100 mg of minocycline, and up to 8.8 mEq/day with the maximum recommended adult dose of 400 mg minocycline/day).<br><br>The specific mechanism for this interaction is unclear as low magnesium concentrations increase the risk for digoxin toxicity and magnesium may be useful to treat digoxin toxicity. Magnesium has been associated with hypotension, cardiac collapse, and a slowing of the ventricular response in patients with atrial fibrillation.<sup>1,2</sup> These effects could lead to some additive or synergistic effects with cardiac glycosides.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Minocin (minocycline) for injection [prescribing information]. Parsippany, NJ: Rempex Pharmaceuticals; April 2015.</p>\n<p>2. Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, Carrara GC. Magnesium and cardiovascular drugs: interactions and therapeutic role. <i>Ann Ital Med Int</i>. 1999;14(1):40-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10528423\">[PubMed 10528423]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","10287":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Asunaprevir may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of statin-related toxicities such as myalgia or myopathy.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> The rosuvastatin AUC was an average of 41% higher with concurrent use of asunaprevir in a clinical study where 20 subjects received rosuvastatin (10 mg single dose) and asunaprevir (200 mg twice daily).<sup>1</sup><br><br>The specific mechanism for this apparent interaction is uncertain, but asunaprevir is both an OATP1B1 substrate, potentially competing with many of the statins for hepatic uptake, and a P-glycoprotein inhibitor, which could alter the transport of some of the statins. Furthermore, asunaprevir is a weak CYP3A4 inducer and may increase the metabolism of simvastatin, lovastatin, and atorvastatin, an effect that could negate or partially offset any OATP1B1- and/or P-glycoprotein-mediated effects. Extra caution and closer monitoring with any asunaprevir-statin combinations seems warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}